##4070858
Behavioral	behavioral	jj_nn1_np1
pharmacology	pharmacology	nn1
research	research	nn1
has	have	vhz
made	make	vvn
important	important	jj
contributions	contribution	nn2
to	to	ii
the	the	at
conceptualization	conceptualization	nn1
of	of	io
addictions	addiction	nn2
and	and	cc
to	to	ii
the	the	at
treatment	treatment	nn1
and	and	cc
prevention	prevention	nn1
of	of	io
substance	substance	nn1
abuse	abuse	nn1
.	.	y
It	it	pph1
has	have	vhz
its	its	z'
intellectual	intellectual	jj_nn1
roots	root	nn2
in	in	ii
the	the	at
experimental	experimental	jj
analysis	analysis	nn1
of	of	io
behavior	behavior	nn1
and	and	cc
close	close	jj_vv0
ties	tie	nn2
with	with	iw
experimental	experimental	jj
and	and	cc
clinical	clinical	jj
pharmacology	pharmacology	nn1
.	.	y
Because	because	cs
substance	substance	nn1
abusers	abuser	nn2
self	self	nn1
administer	administer	vv0
drugs	drug	nn2
repeatedly	repeatedly	rr
,	,	y
this	this	dd1
presents	present	vvz
the	the	at
opportunity	opportunity	nn1
for	for	if
learning	learn	vvg_nn1
to	to	to
occur	occur	vvi
.	.	y
The	the	at
application	application	nn1
of	of	io
learning	learning	nn1
theory	theory	nn1
to	to	ii
the	the	at
laboratory	laboratory	nn1
study	study	nn1
of	of	io
drug	drug	nn1
effects	effect	nn2
in	in	ii_rp@
both	both	rr
animals	animal	nn2
and	and	cc
humans	human	nn2
has	have	vhz
been	be	vbn
a	a	at1
major	major	jj
contribution	contribution	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
.	.	y
Principles	principle	nn2
derived	derive	vvn
from	from	ii
over	over	rg
40	40	mc
years	year	nnt2
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
are	be	vbr
now	now	rt
widely	widely	rr
accepted	accept	vvn_vvd
in	in	ii
the	the	at
addiction	addiction	nn1
field	field	nn1
and	and	cc
have	have	vh0
contributed	contribute	vvn
to	to	ii
the	the	at
development	development	nn1
of	of	io
both	both	db2_rr
pharmacological	pharmacological	jj
and	and	cc
behavioral	behavioral	jj_nn1
treatments	treatment	nn2
.	.	y
Drug	drug	nn1
abuse	abuse	nn1
prevention	prevention	nn1
through	through	ii
the	the	at
assessment	assessment	nn1
of	of	io
the	the	at
abuse	abuse	nn1
liability	liability	nn1
of	of	io
new	new	jj
medications	medication	nn2
has	have	vhz
also	also	rr
been	be	vbn
an	a	at1
important	important	jj
applied	applied	jj
area	area	nn1
of	of	io
research	research	nn1
in	in	ii
the	the	at
field	field	nn1
.	.	y
Personal	personal	jj
reflections	reflection	nn2
of	of	io
three	three	mc
behavioral	behavioral	jj
pharmacologists	pharmacologist	nn2
provide	provide	vv0
examples	example	nn2
of	of	io
important	important	jj
influences	influence	nn2
in	in	ii
the	the	at
field	field	nn1
.	.	y
<p>	<p>	y
Behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
grew	grow	vvd
from	from	ii
roots	root	nn2
in	in	ii
experimental	experimental	jj
psychology	psychology	nn1
and	and	cc
the	the	at
experimental	experimental	jj
analysis	analysis	nn1
of	of	io
behavior	behavior	nn1
to	to	to
address	address	vvi
drug	drug	nn1
effects	effect	nn2
on	on	ii
behavior	behavior	nn1
and	and	cc
how	how	rrq
the	the	at
contexts	context	nn2
in	in	ii
which	which	ddq
drugs	drug	nn2
are	be	vbr
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
historical	historical	jj
overview	overview	nn1
of	of	io
contributions	contribution	nn2
of	of	io
both	both	rr
animal	animal	nn1_jj%
and	and	cc
human	human	jj
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
to	to	ii
the	the	at
study	study	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
.	.	y
Behavioral	behavioral	jj_nn1
pharmacologists	pharmacologist	nn2
developed	develop	vvd_vvn
important	important	jj
laboratory	laboratory	nn1
animal	animal	nn1
models	model	nn2
for	for	if
the	the	at
learned	learned	jj@
aspects	aspect	nn2
of	of	io
drug	drug	nn1
abuse	abuse	nn1_vv0@
that	that	cst
subsequently	subsequently	rr
led	lead	vvn_vvd
to	to	to
close	close	vvi
counterparts	counterpart	nn2
in	in	ii
human	human	jj_nn1
research	research	nn1
.	.	y
Some	some	dd
of	of	io
the	the	at
most	most	rgt
important	important	jj
models	model	nn2
use	use	vv0
studies	study	nn2
of	of	io
the	the	at
stimulus	stimulus	nn1
properties	property	nn2
of	of	io
drugs	drug	nn2
where	where	cs_rrq
they	they	pphs2
function	function	vv0@
as	as	csa_rg@
conditioned	condition	vvn_jj
or	or	cc
unconditioned	unconditioned	jj
stimuli	stimulus	nn2
in	in	ii
classical	classical	jj
conditioning	conditioning	nn1_jj
and	and	cc
discriminative	discriminative	jj
or	or	cc
reinforcing	reinforce	vvg_jj@
stimuli	stimulus	nn2
in	in	ii
operant	operant	jj_nn1
learning	learning	nn1
.	.	y
Important	important	jj
applications	application	nn2
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
have	have	vh0
helped	help	vvn
form	form	nn1_vv0
learning	learning	nn1_vvg
theories	theory	nn2
of	of	io
addiction	addiction	nn1
,	,	y
assess	assess	vv0
the	the	at
abuse	abuse	nn1
potential	potential	nn1
of	of	io
medications	medication	nn2
,	,	y
and	and	cc
develop	develop	vv0
both	both	rr
pharmacological	pharmacological	jj
and	and	cc
behavioral	behavioral	jj_nn1
treatments	treatment	nn2
for	for	if
addiction	addiction	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
ANIMAL	animal	nn1
BEHAVIORAL		np1_nn1_jj
PHARMACOLOGY	pharmacology	np1_nn1
Behavioral		np1_jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
grew	grow	vvd
from	from	ii
the	the	at
interdisciplinary	interdisciplinary	jj
work	work	nn1
of	of	io
pharmacologists	pharmacologist	nn2
and	and	cc
behavioral	behavioral	jj_nn1
scientists	scientist	nn2
.	.	y
One	one	mc1
domain	domain	nn1
of	of	io
behavioral	behavioral	jj_nn1
sciences	science	nn2
particularly	particularly	rr
well-represented	well-represented	jj_nn1
among	among	ii
early	early	jj
researchers	researcher	nn2
was	be	vbdz
the	the	at
experimental	experimental	jj
analysis	analysis	nn1
of	of	io
behavior	behavior	nn1
as	as	csa
articulated	articulate	vvn
by	by	ii
Skinner	skinner	np1
(	(	y
1938	1938	mc
)	)	y
,	,	y
a	a	at1
field	field	nn1
of	of	io
research	research	nn1
that	that	cst
utilized	utilize	vvd
scientific	scientific	jj
methods	method	nn2
described	describe	vvn
by	by	ii
Sidman	sidman	np1_nn1
(	(	y
1960	1960	mc
)	)	y
.	.	y
An	a	at1
important	important	jj
early	early	jj
focus	focus	nn1
of	of	io
the	the	at
work	work	nn1
,	,	y
exemplified	exemplify	vvn
by	by	ii
the	the	at
work	work	nn1
of	of	io
Dews	dew	nn2
and	and	cc
others	others	nn2
,	,	y
was	be	vbdz
on	on	ii
the	the	at
interactions	interaction	nn2
of	of	io
drugs	drug	nn2
with	with	iw
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Kelleher	kelleher	np1
,	,	y
1970	1970	mc
)	)	y
.	.	y
In	in	ii
well-controlled	well-controlled	jj_nn1
laboratory	laboratory	nn1
studies	study	nn2
in	in	ii
animals	animal	nn2
,	,	y
it	it	pph1
was	be	vbdz
shown	show	vvn
that	that	cst
the	the	at
specific	specific	jj
effect	effect	nn1
that	that	cst
a	a	at1
drug	drug	nn1
produced	produce	vvn_vvd
on	on	ii
behavior	behavior	nn1
depended	depend	vvd_vvn
,	,	y
to	to	ii
a	a	at1
large	large	jj
extent	extent	nn1
,	,	y
on	on	ii
the	the	at
behavioral	behavioral	jj_nn1
history	history	nn1
of	of	io
the	the	at
animal	animal	nn1
!	!	y
and	and	cc
on	on	ii
what	what	ddq
the	the	at
animal	animal	nn1
had	have	vhd
been	be	vbn
trained	train	vvn
to	to	to
do	do	vdi
when	when	cs
the	the	at
drug	drug	nn1
was	be	vbdz
administered	administer	vvn
.	.	y
Depending	depending	ii21
on	on	ii22
the	the	at
specified	specified	jj@
schedule	schedule	nn1
of	of	io
reinforcement	reinforcement	nn1
,	,	y
amphetamine	amphetamine	nn1_vv0
could	could	vm
either	either	rr
stimulate	stimulate	vvi
or	or	cc
suppress	suppress	vvi
behavior	behavior	nn1
.	.	y
The	the	at
observation	observation	nn1
in	in	ii
the	the	at
animal	animal	nn1
laboratory	laboratory	nn1
that	that	cst_dd1
drug	drug	nn1
effects	effect	nn2
were	be	vbdr
not	not	xx
the	the	at
immutable	immutable	jj
result	result	nn1
of	of	io
their	their	appge
pharmacological	pharmacological	jj
properties	property	nn2
but	but	ccb
could	could	vm
differ	differ	vvi
from	from	ii
animal	animal	nn1
to	to	ii
animal	animal	nn1
,	,	y
from	from	rr41
time	time	rr42
to	to	rr43
time	time	rr44
,	,	y
and	and	cc
from	from	ii
circumstance	circumstance	nn1
to	to	ii
circumstance	circumstance	nn1
,	,	y
was	be	vbdz
consistent	consistent	jj
with	with	iw
the	the	at
observation	observation	nn1
of	of	io
similar	similar	jj
response	response	nn1
variability	variability	nn1
in	in	ii
humans	human	nn2
.	.	y
Previously	previously	rr
,	,	y
individual	individual	jj
differences	difference	nn2
in	in	ii
addictive	addictive	jj
behavior	behavior	nn1
evident	evident	jj
in	in	ii
the	the	at
general	general	jj_nn1
population	population	nn1
were	be	vbdr
attributed	attribute	vvn
to	to	ii
moral	moral	jj
weakness	weakness	nn1
or	or	cc
personality	personality	nn1
defects	defect	nn2
in	in	ii
substance	substance	nn1
abusers	abuser	nn2
or	or	cc
perhaps	perhaps	rr
to	to	ii_to
genetically	genetically	rr
inherited	inherit	vvn_vvd_jj@
flaws	flaw	nn2
.	.	y
Whatever	whatever	ddqv
the	the	at
basis	basis	nn1
,	,	y
substance	substance	nn1
abuse	abuse	nn1
and	and	cc
addiction	addiction	nn1
were	be	vbdr
seen	see	vvn
as	as	csa_ii@
problems	problem	nn2
of	of	io
a	a	at1
flawed	flawed	jj
minority	minority	nn1
.	.	y
Behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
offered	offer	vvd_vvn
a	a	at1
perspective	perspective	nn1
from	from	ii
which	which	ddq
to	to	to
study	study	vvi
the	the	at
way	way	nn1
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
produced	produce	vvd_vvn
their	their	appge
behavioral	behavioral	nn1_jj
and	and	cc
addictive	addictive	jj
effects	effect	nn2
that	that	cst_dd1
could	could	vm
account	account	vvi
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
animal	animal	nn1_jj%
behavioral	behavioral	nn1_jj
pharmacologists	pharmacologist	nn2
studied	study	vvd_vvn
classes	class	nn2
of	of	io
drugs	drug	nn2
beyond	beyond	ii
those	those	dd2
with	with	iw
abuse	abuse	nn1
potential	potential	nn1
(	(	y
Pickens	pickens	np1
,	,	y
1977	1977	mc
)	)	y
.	.	y
Behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
evolved	evolve	vvn_vvd
in	in	ii_rp@
parallel	parallel	nn1_jj_rr
with	with	iw
the	the	at
development	development	nn1
of	of	io
many	many	da2
new	new	jj
types	type	nn2
of	of	io
psychotherapeutic	psychotherapeutic	jj
medication	medication	nn1
's	's	ge
(	(	y
e.g.	eg	rex
,	,	y
antipsychotics	antipsychotics	nn2_nn1
,	,	y
antidepressants	anti-depressant	nn2
,	,	y
and	and	cc
anxiolytics	anxiolytic	nn2_nn1
)	)	y
.	.	y
Indeed	indeed	rr
,	,	y
behavioral	behavioral	jj_nn1
pharmacologists	pharmacologist	nn2
were	be	vbdr
active	active	jj
in	in	ii
developing	developing	jj_vvg
animal	animal	nn1
test	test	nn1_vv0
procedures	procedure	nn2
to	to	to
model	model	vvi
and	and	cc
predict	predict	vvi
desired	desired	jj@_vvn
clinical	clinical	jj
responses	response	nn2
to	to	ii
these	these	dd2
medications	medication	nn2
.	.	y
For	for	rex21
example	example	rex22
,	,	y
drugs	drug	nn2
with	with	iw
anti-anxiety	anti-anxiety	jj
effects	effect	nn2
were	be	vbdr
often	often	rr
shown	show	vvn
to	to	to
increase	increase	vvi
rates	rate	nn2
of	of	io
lever-pressing	lever-pressing	jj_nn1
behavior	behavior	nn1
of	of	io
rats	rat	nn2
or	or	cc
keypecking	keypecking	vvg_jj@
behavior	behavior	nn1
of	of	io
pigeons	pigeon	nn2
that	that	cst
were	be	vbdr
decreased	decrease	vvn
by	by	ii
punishment	punishment	nn1
(	(	y
Barrett	barrett	np1
,	,	y
2002	2002	mc
)	)	y
.	.	y
The	the	at
disinhibition	disinhibition	nn1
of	of	io
behavior	behavior	nn1
suppressed	suppress	vvn
by	by	ii
punishment	punishment	nn1
has	have	vhz
become	become	vvn@
a	a	at1
standard	standard	jj
behavioral	behavioral	jj_nn1
assay	assay	nn1
for	for	if
the	the	at
anti-anxiety	anti-anxiety	jj_nn1
activity	activity	nn1
of	of	io
drugs	drug	nn2
.	.	y
Similarly	similarly	rr
,	,	y
conditioned	conditioned	jj
shock	shock	nn1
avoidance	avoidance	nn1
responding	respond	vvg
was	be	vbdz
employed	employ	vvn
as	as	ii
an	a	at1
assay	assay	nn1
for	for	if
antipsychotic	anti-psychotic	jj
medications	medication	nn2
used	use	vmk
to	to	to
treat	treat	vvi
schizophrenia	schizophrenia	nn1
.	.	y
This	this	dd1
historical	historical	jj
association	association	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
with	with	iw
psychotherapeutic	psychotherapeutic	jj
medication	medication	nn1
development	development	nn1
has	have	vhz
been	be	vbn
well	well	rr
described	describe	vvn
(	(	y
McKim	mckim	np1
,	,	y
2007	2007	mc
)	)	y
.	.	y
<p>	<p>	y
Thompson	thompson	np1
and	and	cc
Schuster	schuster	np1_nn1
's	's	ge
textbook	textbook	nn1
(	(	y
1968	1968	mc
)	)	y
offered	offer	vvd
the	the	at
first	first	md
comprehensive	comprehensive	jj
explanation	explanation	nn1
of	of	io
the	the	at
application	application	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
to	to	ii
the	the	at
study	study	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
.	.	y
The	the	at
appearance	appearance	nn1
of	of	io
this	this	dd1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
stimulus	stimulus	nn1
properties	property	nn2
of	of	io
drugs	drug	nn2
(	(	y
Pickens	pickens	np1
&;		null
Thompson	thompson	np1
,	,	y
1970	1970	mc
)	)	y
.	.	y
A	a	at1_zz1
powerful	powerful	jj
theory	theory	nn1
that	that	cst
guided	guide	vvd
much	much	da1
of	of	io
this	this	dd1
research	research	nn1
is	be	vbz
that	that	cst
drugs	drug	nn2
could	could	vm
perform	perform	vvi
the	the	at
same	same	da
stimulus	stimulus	nn1
functions	function	nn2_vvz@
in	in	ii
stimulus-response	stimulus-response	jj_nn1
learning	learning	nn1
as	as	csa
external	external	jj
environmental	environmental	jj
stimuli	stimulus	nn2
.	.	y
An	a	at1
important	important	jj
early	early	jj_rr
influence	influence	nn1_vv0
on	on	ii
this	this	dd1
theory	theory	nn1
was	be	vbdz
the	the	at
work	work	nn1
of	of	io
Wikler	wikler	np1_nn1
(	(	y
1973	1973	mc
)	)	y
on	on	ii
the	the	at
ability	ability	nn1
of	of	io
environments	environment	nn2
in	in	ii
which	which	ddq
drug	drug	nn1_vv0%
abusers	abuser	nn2
lived	live	vvd_vvn
to	to	to
trigger	trigger	vvi
drug	drug	nn1
craving	crave	vvg_nn1@
,	,	y
withdrawal	withdrawal	nn1
symptoms	symptom	nn2
,	,	y
and	and	cc
relapse	relapse	nn1_vv0
.	.	y
Wikler	wikler	np1@_nn1
explained	explain	vvd
this	this	dd1
as	as	ii_csa
a	a	at1
form	form	nn1
of	of	io
classical	classical	jj
conditioning	conditioning	nn1_jj
where	where	cs_rrq
the	the	at
external	external	jj
cues	cue	nn2
were	be	vbdr
the	the	at
conditioned	conditioned	jj
stimuli	stimulus	nn2
paired	pair	vvn_vvd
with	with	iw
drug-related	drug-related	jj
unconditioned	unconditioned	jj
stimuli	stimulus	nn2
that	that	cst
came	come	vvd
to	to	to
elicit	elicit	vvi
conditioned	conditioned	jj
responses	response	nn2
experienced	experience	vvn_vvd
as	as	csa_ii@
craving	crave	vvg_jj@
and	and	cc
relapse	relapse	nn1_vv0
.	.	y
The	the	at
development	development	nn1
of	of	io
animal	animal	nn1
models	model	nn2
for	for	if
the	the	at
classical	classical	jj
conditioning	conditioning	nn1
of	of	io
drug	drug	nn1
effects	effect	nn2
greatly	greatly	rr
expanded	expanded	jj_vvn
research	research	nn1
in	in	ii
this	this	dd1
area	area	nn1
.	.	y
<p>	<p>	y
Another	another	dd1
important	important	jj
advance	advance	nn1
stemming	stem	vvg
from	from	ii
the	the	at
integration	integration	nn1
of	of	io
these	these	dd2
two	two	mc
sciences	science	nn2
was	be	vbdz
the	the	at
demonstration	demonstration	nn1
that	that	cst
drugs	drug	nn2
could	could	vm
function	function	vvi
as	as	rg@_csa_ii@
reinforcing	reinforcing	jj@_vvg
stimuli	stimulus	nn2
in	in	ii
operant	operant	jj_nn1
conditioning	conditioning	nn1
procedures	procedure	nn2
similar	similar	jj
to	to	ii
other	other	jj
reinforcers	reinforcer	nn2
,	,	y
such	such	ii21
as	as	ii22
food	food	nn1
.	.	y
Early	early	jj_rr
studies	study	nn2
by	by	ii
Thompson	thompson	np1
and	and	cc
Schuster	schuster	np1_nn1
(	(	y
1964	1964	mc
)	)	y
and	and	cc
Deneau	deneau	np1_nn1
,	,	y
Yanagita	yanagita	np1
,	,	y
and	and	cc
Seevers	seevers	np1
(	(	y
1969	1969	mc
)	)	y
in	in	ii
monkeys	monkey	nn2
and	and	cc
by	by	ii
Weeks	weeks	np1@_nnt2
(	(	y
1962	1962	mc
)	)	y
in	in	ii
rats	rat	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
these	these	dd2
studies	study	nn2
,	,	y
animals	animal	nn2
pressed	press	vvd_vvn
response	response	nn1
levers	lever	nn2
to	to	to
obtain	obtain	vvi
intravenous	intravenous	jj
drug	drug	nn1
injections	injection	nn2
.	.	y
It	it	pph1
was	be	vbdz
found	find	vvn
that	that	cst
animals	animal	nn2
would	would	vm
self-administer	self-administer	vvi
most	most	dat
drugs	drug	nn2
abused	abuse	vvn
by	by	ii
people	people	nn
.	.	y
Extensive	extensive	jj
cross-species	cross-species	nn_jj
and	and	cc
cross-drug	cross-drug	jj_nn1
commonalities	commonality	nn2
have	have	vh0
been	be	vbn
noted	note	vvn
in	in	ii
the	the	at
relationships	relationship	nn2
of	of	io
pharmacological	pharmacological	jj
and	and	cc
environmental	environmental	jj
and	and	cc
behavioral	behavioral	jj_nn1
factors	factor	nn2
to	to	ii
drug	drug	nn1
self-administration	self-administration	nn1
(	(	y
Griffiths	griffiths	np1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
&;		null
Henningfield	henningfield	np1
,	,	y
1980	1980	mc
)	)	y
.	.	y
Also	also	rr
,	,	y
some	some	dd
substances	substance	nn2
regularly	regularly	rr
consumed	consume	vvn
by	by	ii
humans	human	nn2
but	but	ccb
not	not	xx
previously	previously	rr
considered	consider	vvn_vvd
addictive	addictive	jj
or	or	cc
dependence	dependence	nn1
producing	produce	vvg
(	(	y
e.g.	eg	rex
,	,	y
tobacco	tobacco	nn1
)	)	y
have	have	vh0
now	now	rt
come	come	vvn
to	to	to
be	be	vbi
seen	see	vvn
and	and	cc
understood	understand	vvn_vvd
within	within	ii
this	this	dd1
same	same	da
framework	framework	nn1
.	.	y
The	the	at
development	development	nn1
of	of	io
animal	animal	nn1
drug	drug	nn1
self-administration	self-administration	nn1_jj
models	model	nn2
is	be	vbz
probably	probably	rr
the	the	at
single	single	jj
greatest	greatest	jjt
scientific	scientific	jj
advance	advance	nn1
that	that	cst
freed	free	vvd
us	us	ppio2
from	from	ii
the	the	at
view	view	nn1
of	of	io
substance	substance	nn1
abuse	abuse	nn1
risk	risk	nn1
and	and	cc
vulnerability	vulnerability	nn1
being	be	vbg
relevant	relevant	jj
only	only	rr
to	to	ii
a	a	at1
flawed	flawed	jj
minority	minority	nn1
of	of	io
the	the	at
population	population	nn1
.	.	y
The	the	at
development	development	nn1
of	of	io
these	these	dd2
animal	animal	nn1_jj%
laboratory	laboratory	nn1
models	model	nn2
was	be	vbdz
a	a	at1
great	great	jj
scientific	scientific	jj
advance	advance	nn1
that	that	cst
highlighted	highlight	vvd
the	the	at
biological	biological	jj
normality	normality	nn1
of	of	io
drug	drug	nn1
reinforcement	reinforcement	nn1
and	and	cc
the	the	at
universality	universality	nn1
,	,	y
or	or	cc
near-universality	near-universality	nn1_jj
,	,	y
of	of	io
vulnerability	vulnerability	nn1
to	to	ii
drug	drug	nn1
reinforcement	reinforcement	nn1
and	and	cc
drug	drug	nn1
abuse	abuse	nn1
.	.	y
<p>	<p>	y
Application	application	nn1
of	of	io
learning	learn	vvg_nn1
principles	principle	nn2
to	to	ii
the	the	at
study	study	nn1
of	of	io
pharmacology	pharmacology	nn1
demonstrated	demonstrate	vvd_vvn
that	that	cst
drugs	drug	nn2
could	could	vm
also	also	rr
function	function	vvi
as	as	rg@_csa
discriminative	discriminative	jj
stimuli	stimulus	nn2
(	(	y
Schuster	schuster	np1
&;		null
Balster	balster	np1_nn1
,	,	y
19,77	19,77	mc
)	)	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
presented	present	vvn
with	with	iw
two	two	mc
response	response	nn1
levers	lever	nn2
;	;	y
only	only	rr
one	one	pn1_mc1
will	will	vm
result	result	vvi
in	in	ii
food	food	nn1
reinforcement	reinforcement	nn1
.	.	y
If	if	cs
the	the	at
animals	animal	nn2
were	be	vbdr
trained	train	vvn
that	that	cst_dd1
pressing	press	vvg
the	the	at
left	left	jj
lever	lever	nn1
is	be	vbz
reinforced	reinforce	vvn
on	on	ii
days	day	nnt2
when	when	rrq
they	they	pphs2
were	be	vbdr
injected	inject	vvn
with	with	iw
an	a	at1
active	active	jj
drug	drug	nn1
and	and	cc
pressing	press	vvg
the	the	at
right	right	jj_nn1
lever	lever	nn1
is	be	vbz
reinforced	reinforce	vvn
on	on	ii
days	day	nnt2
when	when	rrq
they	they	pphs2
were	be	vbdr
injected	inject	vvn
with	with	iw
placebo	placebo	nn1
,	,	y
they	they	pphs2
soon	soon	rr
learned	learn	vvn_vvd
to	to	to
detect	detect	vvi
whether	whether	csw
they	they	pphs2
were	be	vbdr
given	give	vvn
the	the	at
active	active	jj
drug	drug	nn1
and	and	cc
demonstrated	demonstrate	vvn
this	this	dd1
by	by	ii
selecting	select	vvg
the	the	at
correct	correct	jj
lever	lever	nn1
.	.	y
This	this	dd1
paradigm	paradigm	nn1
provides	provide	vvz
a	a	at1
mechanism	mechanism	nn1
to	to	to
measure	measure	vvi
and	and	cc
characterize	characterize	vvi
the	the	at
interoceptive	interoceptive	jj
effects	effect	nn2
of	of	io
drugs	drug	nn2
in	in	ii
nonverbal	nonverbal	jj_nn1
species	species	nn
.	.	y
This	this	dd1
technique	technique	nn1
has	have	vhz
been	be	vbn
effectively	effectively	rr
applied	apply	vvn_vvd
to	to	ii
the	the	at
characterization	characterization	nn1
and	and	cc
classification	classification	nn1
of	of	io
novel	novel	jj_nn1
entities	entity	nn2
according	according	ii21
to	to	ii22
their	their	appge
similarities	similarity	nn2
and	and	cc
dissimilarities	dissimilarity	nn2
by	by	ii
comparing	compare	vvg
these	these	dd2
discriminative	discriminative	jj
stimulus	stimulus	nn1
effects	effect	nn2
to	to	ii
a	a	at1
standard	standard	jj_nn1
drug	drug	nn1
with	with	iw
known	known	jj@
effects	effect	nn2
.	.	y
Drug	drug	nn1
discrimination	discrimination	nn1
methods	method	nn2
have	have	vh0
also	also	rr
been	be	vbn
used	use	vvn
to	to	to
study	study	vvi
the	the	at
internal	internal	jj
states	state	nn2
related	relate	vvn_vvd
to	to	ii
withdrawal	withdrawal	nn1
from	from	ii
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
through	through	ii
training	train	vvg@
the	the	at
discrimination	discrimination	nn1
of	of	io
different	different	jj
physiologic	physiologic	jj
states	state	nn2
.	.	y
<p>	<p>	y
Tolerance	tolerance	nn1
,	,	y
previously	previously	rr
thought	think	vvn_vvd
to	to	to
be	be	vbi
a	a	at1
purely	purely	rr
pharmacological	pharmacological	jj
process	process	nn1
,	,	y
is	be	vbz
now	now	rt
known	know	vvn
to	to	to
be	be	vbi
in	in	rr21
part	part	rr22
a	a	at1
learning	learning	nn1
process	process	nn1
(	(	y
Schuster	schuster	np1_nn1
,	,	y
Dockens	dockens	np1_nn2
,	,	y
&;		null
Woods	woods	np1
,	,	y
1966	1966	mc
)	)	y
.	.	y
Dramatic	dramatic	jj
differences	difference	nn2
in	in	ii
the	the	at
extent	extent	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
depending	depending	ii21
on	on	ii22
whether	whether	csw
animals	animal	nn2
have	have	vh0
an	a	at1
opportunity	opportunity	nn1
to	to	ii
practice	practice	nn1
the	the	at
behavior	behavior	nn1
during	during	ii
active	active	jj
drug	drug	nn1
exposure	exposure	nn1
.	.	y
Even	even	rr
analgesic	analgesic	jj@_nn1
tolerance	tolerance	nn1
has	have	vhz
a	a	at1
strong	strong	jj
learning	learning	nn1
component	component	nn1
.	.	y
<p>	<p>	y
Animal	animal	nn1
behavioral	behavioral	nn1_jj
pharmacology	pharmacology	nn1
research	research	nn1
on	on	ii
the	the	at
environmental	environmental	jj
determinants	determinant	nn2
of	of	io
drug	drug	nn1
action	action	nn1
and	and	cc
on	on	ii
the	the	at
stimulus	stimulus	nn1
properties	property	nn2
of	of	io
drugs	drug	nn2
provided	provide	vvd_cs_vvn
the	the	at
scientific	scientific	jj
basis	basis	nn1
for	for	if
a	a	at1
learning	learning	nn1
theory	theory	nn1
of	of	io
addiction	addiction	nn1
(	(	y
Barrett	barrett	np1
,	,	y
2002	2002	mc
;	;	y
Thompson	thompson	np1
&;		null
Schuster	schuster	np1
,	,	y
1968	1968	mc
)	)	y
.	.	y
This	this	dd1
theory	theory	nn1
dominates	dominate	vvz
contemporary	contemporary	jj
conceptualizations	conceptualization	nn2
of	of	io
how	how	rrq
people	people	nn
come	come	vv0
to	to	to
develop	develop	vvi
and	and	cc
sustain	sustain	vvi
drug	drug	nn1
abuse	abuse	nn1
and	and	cc
how	how	rrq
the	the	at
manifestations	manifestation	nn2
of	of	io
the	the	at
problem	problem	nn1
can	can	vm
differ	differ	vvi
from	from	ii
person	person	nn1
to	to	ii
person	person	nn1
,	,	y
place	place	vv0
to	to	to
place	place	vvi
,	,	y
and	and	cc
time	time	nnt1
to	to	ii
time	time	nnt1
.	.	y
With	with	iw
these	these	dd2
animal	animal	nn1_jj%
models	model	nn2
,	,	y
one	one	pn1
could	could	vm
readily	readily	rr
incorporate	incorporate	vvi
other	other	jj
scientific	scientific	jj
developments	development	nn2
in	in	ii
both	both	db2
the	the	at
behavioial	behavioial	jj
(	(	y
e.g.	eg	rex
behavioral	behavioral	jj_nn1
economics	economics	nn1
,	,	y
decision	decision	nn1
theory	theory	nn1
)	)	y
and	and	cc
pharmacological	pharmacological	jj
(	(	y
e.g.	eg	rex
receptor	receptor	nn1
theory	theory	nn1
,	,	y
molecular	molecular	jj
biology	biology	nn1
)	)	y
sciences	science	nn2
into	into	ii
these	these	dd2
methodologies	methodology	nn2
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
HUMAN	human	jj
BEHAVIORAL	behavioral	jj_nn1_np1
PHARMACOLOGY	pharmacology	nn1_np1
A	a	zz1
remarkable	remarkable	jj
strength	strength	nn1
of	of	io
these	these	dd2
behavioral	behavioral	jj
pharmacology	pharmacology	nn1
models	model	nn2
in	in	ii
laboratory	laboratory	nn1
animals	animal	nn2
was	be	vbdz
their	their	appge
seamless	seamless	jj
transition	transition	nn1
to	to	ii
human	human	jj_nn1
laboratory	laboratory	nn1
research	research	nn1
.	.	y
Indeed	indeed	rr
,	,	y
many	many	da2
of	of	io
the	the	at
procedures	procedure	nn2
used	use	vvn_vvd
in	in	ii
human	human	jj_nn1
laboratory	laboratory	nn1
studies	study	nn2
have	have	vh0
almost	almost	rr
direct	direct	jj
counterparts	counterpart	nn2
in	in	ii
animal	animal	nn1
models	model	nn2
.	.	y
This	this	dd1
is	be	vbz
an	a	at1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
compared	compare	vvn
with	with	iw
the	the	at
animal	animal	nn1
to	to	ii
human	human	jj_nn1
translation	translation	nn1
problems	problem	nn2
that	that	cst
occur	occur	vv0
in	in	ii_rp@
other	other	jj
fields	field	nn2
.	.	y
Perhaps	perhaps	rr
the	the	at
earliest	early	jjt_rrt
study	study	nn1_vv0@
to	to	to
adapt	adapt	vvi
these	these	dd2
behavioral	behavioral	jj
methods	method	nn2
to	to	ii
issues	issue	nn2
of	of	io
substance	substance	nn1
abuse	abuse	nn1
in	in	ii
humans	human	nn2
examined	examine	vvd_vvn
the	the	at
basic	basic	jj
behavioral	behavioral	jj_nn1
parameters	parameter	nn2
of	of	io
alcohol	alcohol	nn1
intake	intake	nn1
using	use	vvg
oral	oral	jj_nn1
self-administration	self-administration	nn1
in	in	ii
alcoholics	alcoholic	nn2
(	(	y
Mello	mello	np1
&;		null
Mendelson	mendelson	np1
,	,	y
1965	1965	mc
)	)	y
.	.	y
Self-administration	self-administration	jj_nn1
procedures	procedure	nn2
were	be	vbdr
subsequently	subsequently	rr
applied	apply	vvn_vvd
to	to	ii
the	the	at
study	study	nn1
of	of	io
illicit	illicit	jj
drugs	drug	nn2
,	,	y
such	such	ii21
as	as	ii22
heroin	heroin	nn1
(	(	y
e.g.	eg	rex
,	,	y
Mello	mello	np1
&;		null
Mendelson	mendelson	np1
,	,	y
1978	1978	mc
)	)	y
and	and	cc
cocaine	cocaine	nn1
(	(	y
Fischman	fischman	np1
&;		null
Schuster	schuster	np1_nn1
,	,	y
1982	1982	mc
)	)	y
,	,	y
in	in	ii
individuals	individual	nn2
with	with	iw
substance	substance	nn1
abuse	abuse	nn1
histories	history	nn2
.	.	y
These	these	dd2
procedures	procedure	nn2
were	be	vbdr
soon	soon	rr
adapted	adapt	vvn_vvd
to	to	to
investigate	investigate	vvi
the	the	at
ability	ability	nn1
of	of	io
potential	potential	jj_nn1
therapeutics	therapeutics	nn1
to	to	to
reduce	reduce	vvi
drug	drug	nn1
taking	take	vvg
,	,	y
such	such	ii21
as	as	ii22
in	in	ii
the	the	at
early	early	jj
work	work	nn1
by	by	ii
Meyer	meyer	np1
,	,	y
McNamee	mcnamee	np1
,	,	y
Mirin	mirin	np1_nn1
,	,	y
and	and	cc
Altman	altman	np1
(	(	y
1976	1976	mc
)	)	y
who	who	pnqs
investigated	investigate	vvd
the	the	at
ability	ability	nn1
of	of	io
naltrexone	naltrexone	nn1
to	to	to
reduce	reduce	vvi
opioid	opioid	jj
self-administration	self-administration	nn1
in	in	ii
heroin	heroin	nn1
addiction	addiction	nn1
.	.	y
Similarly	similarly	rr
,	,	y
drug	drug	nn1
discrimination	discrimination	nn1
procedures	procedure	nn2
were	be	vbdr
adapted	adapt	vvn
for	for	if
the	the	at
human	human	jj_nn1
laboratory	laboratory	nn1
(	(	y
Chait	chait	np1_vv0_nn1
,	,	y
Uhlenhuth	uhlenhuth	np1_nn1
,	,	y
&;		null
Johanson	johanson	np1
,	,	y
1984	1984	mc
;	;	y
Preston	preston	np1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
Bickel	bickel	np1
,	,	y
&;		null
Liebson		np1
,	,	y
1987	1987	mc
)	)	y
,	,	y
thus	thus	rr
providing	provide	vvg
the	the	at
first	first	md
opportunity	opportunity	nn1
to	to	to
examine	examine	vvi
the	the	at
relative	relative	jj_nn1
concordance	concordance	nn1
of	of	io
discriminative	discriminative	jj
stimulus	stimulus	nn1
effects	effect	nn2
and	and	cc
subjective	subjective	jj
descriptions	description	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
)	)	y
.	.	y
The	the	at
drug	drug	nn1
discrimination	discrimination	nn1
procedure	procedure	nn1
has	have	vhz
now	now	rt
been	be	vbn
more	more	rgr
broadly	broadly	rr
applied	apply	vvn_vvd
to	to	ii
the	the	at
study	study	nn1
of	of	io
various	various	jj
drug	drug	nn1
classes	class	nn2
in	in	ii
humans	human	nn2
,	,	y
including	including	ii_vvg@
opioids	opioid	nn2
,	,	y
stimulants	stimulant	nn2
,	,	y
and	and	cc
sedatives	sedative	nn2
.	.	y
These	these	dd2
laboratory	laboratory	nn1
procedures	procedure	nn2
also	also	rr
capitalized	capitalize	vvd_vvn@
on	on	ii
the	the	at
extensive	extensive	jj
body	body	nn1
of	of	io
clinical	clinical	jj
pharmacology	pharmacology	nn1
research	research	nn1
with	with	iw
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
that	that	cst
had	have	vhd
been	be	vbn
conducted	conduct	vvn
earlier	early	rrr
,	,	y
largely	largely	rr
at	at	ii
the	the	at
Federal	federal	jj
Lexington	lexington	nn1@_np1
Narcotics	narcotic	nn2
Prison	prison	nn1
Farm	farm	nn1
.	.	y
Early	early	jj_rr
investigators	investigator	nn2
in	in	ii
this	this	dd1
field	field	nn1
developed	develop	vvd_vvn
empirically	empirically	rr
derived	derive	vvn_vvd
subjective	subjective	jj
questionnaires	questionnaire	nn2
to	to	to
characterize	characterize	vvi
and	and	cc
categorize	categorize	vvi
drug	drug	nn1
action	action	nn1
;	;	y
these	these	dd2
were	be	vbdr
incorporated	incorporate	vvn
into	into	ii
human	human	jj_nn1
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
studies	study	nn2
and	and	cc
are	be	vbr
still	still	rr
in	in	ii
use	use	nn1
(	(	y
e.g.	eg	rex
,	,	y
the	the	at
Addiction	addiction	npx
Research	research	nn1
Center	center	nn1
Inventory	inventory	nn1
short	short	jj_rr@
form	form	nn1_vv0
,	,	y
Martin	martin	np1
,	,	y
Sloan	sloan	np1_nn1
,	,	y
Sapira	sapira	np1
,	,	y
&;		null
Jasinski	jasinski	np1_nn1
,	,	y
1971	1971	mc
)	)	y
.	.	y
The	the	at
basic	basic	jj
principles	principle	nn2
of	of	io
reinforcement	reinforcement	nn1
have	have	vh0
been	be	vbn
extensively	extensively	rr
applied	apply	vvn_vvd
to	to	ii
the	the	at
development	development	nn1
of	of	io
effective	effective	jj
treatments	treatment	nn2
for	for	if
substance	substance	nn1
abuse	abuse	nn1
in	in	ii
the	the	at
field	field	nn1
of	of	io
contingency	contingency	nn1
management	management	nn1
,	,	y
which	which	ddq
employs	employ	vvz
specified	specified	jj@
reinforcers	reinforcer	nn2
to	to	to
increase	increase	vvi
the	the	at
rate	rate	nn1
of	of	io
therapeutically	therapeutically	rr
beneficial	beneficial	jj
behaviors	behavior	nn2
in	in	ii
substance	substance	nn1
abusers	abuser	nn2
(	(	y
Higgins	higgins	np1
et	et	ra21
al.	al	ra22
,	,	y
1993	1993	mc
;	;	y
Silverman	silverman	np1
et	et	ra21
al.	al	ra22
,	,	y
2002	2002	mc
)	)	y
.	.	y
Each	each	dd1
of	of	io
these	these	dd2
areas	area	nn2
of	of	io
investigation	investigation	nn1
was	be	vbdz
derived	derive	vvn
directly	directly	rr
from	from	ii
the	the	at
basic	basic	jj
principles	principle	nn2
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
first	first	md
revealed	reveal	vvn_vvd
in	in	ii
the	the	at
animal	animal	nn1
laboratory	laboratory	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
field	field	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
liability	liability	nn1
assessment	assessment	nn1
is	be	vbz
one	one	pn1
that	that	cst
has	have	vhz
developed	develop	vvn
extensively	extensively	rr
over	over	ii_rp
the	the	at
past	past	jj
four	four	mc
decades	decade	nnt2
(	(	y
Balster	balster	np1
&;		null
Bigelow	bigelow	np1_nn1
,	,	y
2003	2003	mc
)	)	y
.	.	y
Behavioral	behavioral	jj
pharmacological	pharmacological	jj
methods	method	nn2
,	,	y
such	such	ii21
as	as	ii22
drug	drug	nn1
self-administration	self-administration	nn1
and	and	cc
drug	drug	nn1
discrimination	discrimination	nn1
,	,	y
lie	lie	vv0
at	at	ii
its	its	z'
core	core	nn1
.	.	y
Conceptually	conceptually	rr
similar	similar	jj
methods	method	nn2
are	be	vbr
used	use	vvn
in	in	ii
animals	animal	nn2
and	and	cc
humans	human	nn2
(	(	y
Balster	balster	np1_nn1
,	,	y
1991	1991	mc
;	;	y
Brady	brady	np1
&;		null
Griffiths	griffiths	np1
,	,	y
1976	1976	mc
;	;	y
Fischman	fischman	np1
&;		null
Mello	mello	np1
,	,	y
1989	1989	mc
)	)	y
,	,	y
with	with	iw
substantial	substantial	jj
cross-species	cross-species	nn_jj
and	and	cc
cross-drug	cross-drug	jj_nn1
commonality	commonality	nn1
in	in	ii
assessment	assessment	nn1
methods	method	nn2
.	.	y
The	the	at
methods	method	nn2
have	have	vh0
become	become	vvn@
considerably	considerably	rr
more	more	rgr
sophisticated	sophisticated	jj
over	over	ii
the	the	at
years	year	nnt2
-	-	-
moving	move	vvg
from	from	ii
methods	method	nn2
that	that	cst
provided	provided	cs_vvd
largely	largely	rr
categorical	categorical	jj
answers	answer	nn2
(	(	y
"	"	y
Is	be	vbz
this	this	dd1
drug	drug	nn1
self-administered	self-administered	nn1
?	?	y
"	"	y
)	)	y
to	to	ii
using	use	vvg
more	more	rgr
fine-grained	fine-grained	jj
choice	choice	nn1
and	and	cc
progressive	progressive	jj
ratio	ratio	nn1
and	and	cc
behavioral	behavioral	jj
economic	economic	jj
assessments	assessment	nn2
that	that	cst_dd1
can	can	vm
better	better	rrr
evaluate	evaluate	vvi
and	and	cc
rank	rank	vvi
order	order	nn1
drugs	drug	nn2
in	in	ii31
terms	terms	ii32
of	of	ii33
their	their	appge
reinforcing	reinforcing	jj@
effectiveness	effectiveness	nn1
,	,	y
robustness	robustness	nn1
,	,	y
and	and	cc
overall	overall	jj_nn1
abuse	abuse	nn1
liability	liability	nn1
.	.	y
<p>	<p>	y
These	these	dd2
assessment	assessment	nn1
methods	method	nn2
of	of	io
abuse	abuse	nn1
liability	liability	nn1
have	have	vh0
also	also	rr
been	be	vbn
adapted	adapt	vvn
for	for	if
testing	test	vvg
potential	potential	jj_nn1
pharmacotherapies		nn2
to	to	to
determine	determine	vvi
whether	whether	csw
they	they	pphs2
reduce	reduce	vv0
the	the	at
effects	effect	nn2
,	,	y
self-administration	self-administration	nn1_jj
,	,	y
and	and	cc
apparent	apparent	jj
abuse	abuse	nn1
liability	liability	nn1
of	of	io
their	their	appge
targeted	targeted	jj%
drug	drug	nn1
of	of	io
abuse	abuse	nn1
.	.	y
These	these	dd2
methods	method	nn2
,	,	y
in	in	ii_rp@
both	both	rr
animal	animal	nn1_jj%
and	and	cc
human	human	jj_nn1
laboratories	laboratory	nn2
,	,	y
have	have	vh0
the	the	at
potential	potential	jj_nn1
to	to	to
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
promising	promising	jj
and	and	cc
deserve	deserve	vv0
further	far	jjr@_rrr
evaluation	evaluation	nn1
in	in	ii
large-scale	large-scale	jj
clinical	clinical	jj
trials	trial	nn2
.	.	y
<p>	<p>	y
Methadone	methadone	vv0_nn1_np1@
,	,	y
buprenorphine	buprenorphine	vv0_nn1
,	,	y
and	and	cc
naltrexone	naltrexone	nn1_vv0
are	be	vbr
the	the	at
drug	drug	nn1
addiction	addiction	nn1
pharmacotherapy	pharmacotherapy	nn1
development	development	nn1
success	success	nn1
stories	story	nn2
of	of	io
the	the	at
past	past	jj_nn1
decades	decade	nnt2
(	(	y
Vocci	vocci	np1_jj_nn1
&;		null
Ling	ling	nn1
,	,	y
2005	2005	mc
)	)	y
.	.	y
Methadone	methadone	np1@_nn1_vv0
achieved	achieve	vvd
its	its	z'
adoption	adoption	nn1
and	and	cc
success	success	nn1
through	through	ii
the	the	at
clinical	clinical	jj
innovation	innovation	nn1
of	of	io
Dole	dole	np1
and	and	cc
Nyswander	nyswander	vv0_nn1_np1
without	without	iw
extensive	extensive	jj
prior	prior	jj
laboratory	laboratory	nn1
research	research	nn1
indicating	indicate	vvg
its	its	z'
use	use	nn1
for	for	if
addiction	addiction	nn1
(	(	y
Dole	dole	np1
&;		null
Nyswander		np1
,	,	y
1965	1965	mc
)	)	y
.	.	y
Buprenorphine	buprenorphine	vv0_nn1_np1@
and	and	cc
naltrexone	naltrexone	nn1_vv0
,	,	y
on	on	ii
the	the	at
other	other	jj
hand	hand	nn1
,	,	y
have	have	vh0
both	both	rr
been	be	vbn
developed	develop	vvn
through	through	ii
sequential	sequential	jj
animal	animal	nn1
and	and	cc
human	human	jj_nn1
laboratory	laboratory	nn1
studies	study	nn2
followed	follow	vvn
by	by	ii
subsequent	subsequent	jj
clinical	clinical	jj
trials	trial	nn2
.	.	y
All	all	db
three	three	mc
are	be	vbr
pharmacological	pharmacological	jj
wonder	wonder	nn1_jj@
drugs	drug	nn2
,	,	y
with	with	iw
great	great	jj
efficacy	efficacy	nn1
in	in	ii
interrupting	interrupt	vvg
addictive	addictive	jj
processes	process	nn2
,	,	y
but	but	ccb
none	none	pn
has	have	vhz
yet	yet	rr
been	be	vbn
fully	fully	rr
embraced	embrace	vvn_vvd
into	into	ii
clinical	clinical	jj
practice	practice	nn1
.	.	y
Both	both	rr
methadone	methadone	vv0
and	and	cc
naltrexone	naltrexone	vv0_nn1
continue	continue	vv0
to	to	to
struggle	struggle	vvi
for	for	if
community	community	nn1
acceptance	acceptance	nn1
.	.	y
Buprenorphine	buprenorphine	nn1_vv0_np1@
is	be	vbz
the	the	at
newcomer	newcomer	nn1
to	to	ii
addiction	addiction	nn1
treatment	treatment	nn1
.	.	y
Its	its	z'
degree	degree	nn1
of	of	io
acceptance	acceptance	nn1
may	may	vm
determine	determine	vvi
the	the	at
willingness	willingness	nn1
of	of	io
pharmaceutical	pharmaceutical	jj
companies	company	nn2
to	to	to
invest	invest	vvi
in	in	ii
the	the	at
development	development	nn1
of	of	io
addiction	addiction	nn1
treatments	treatment	nn2
.	.	y
Buprenorphine	buprenorphine	nn1_vv0_np1@
is	be	vbz
especially	especially	rr
interesting	interesting	jj
,	,	y
since	since	cs
its	its	z'
primary	primary	nn1
marketed	market	vvd_vvn
dosage	dosage	nn1
form	form	nn1
(	(	y
the	the	at
buprenorphinenaloxone	buprenorphinenaloxone	nn1
combination	combination	nn1
)	)	y
is	be	vbz
an	a	at1
engineered	engineered	jj
dosage	dosage	nn1
form	form	nn1_vv0
specifically	specifically	rr
designed	design	vvn_vvd
to	to	to
incorporate	incorporate	vvi
reinforcement	reinforcement	nn1
and	and	cc
punishment	punishment	nn1
to	to	to
encourage	encourage	vvi
appropriate	appropriate	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
2003	2003	mc
)	)	y
.	.	y
If	if	cs
the	the	at
medication	medication	nn1
is	be	vbz
taken	take	vvn
as	as	csa
directed	direct	vvn
,	,	y
only	only	rr
the	the	at
reinforcing	reinforcing	jj@
buprenorphine	buprenorphine	nn1
achieves	achieve	vvz
significant	significant	jj
biodelivery	biodelivery	nn1
.	.	y
However	however	rr
,	,	y
if	if	cs
taken	take	vvn
inappropriately	inappropriately	rr
(	(	y
i.e.	ie	rex
,	,	y
by	by	ii
injection	injection	nn1
)	)	y
,	,	y
the	the	at
antagonist	antagonist	nn1
naloxone	naloxone	nn1_vv0
,	,	y
portion	portion	nn1
is	be	vbz
fully	fully	rr
delivered	deliver	vvn_vvd
and	and	cc
can	can	vm
precipitate	precipitate	vvi
an	a	at1
aversive	aversive	jj
withdrawal	withdrawal	nn1
reaction	reaction	nn1
in	in	ii
dependent	dependent	jj
individuals	individual	nn2
(	(	y
Stoller	stoller	np1_nn1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
Walsh	walsh	np1
,	,	y
&;		null
Strain	strain	vv0_nn1_np1@
,	,	y
2001	2001	mc
)	)	y
.	.	y
<p>	<p>	y
The	the	at
value	value	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
to	to	ii
the	the	at
substance	substance	nn1
abuse	abuse	nn1
field	field	nn1
is	be	vbz
reflected	reflect	vvn
in	in	rr21
part	part	rr22
by	by	ii
the	the	at
growth	growth	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
,	,	y
it	it	pph1
is	be	vbz
also	also	rr
reflected	reflect	vvn_vvd
in	in	ii
the	the	at
use	use	nn1
of	of	io
behavioral	behavioral	jj
pharmacological	pharmacological	jj
methods	method	nn2
by	by	ii
other	other	jj
disciplinary	disciplinary	jj
approaches	approach	nn2
to	to	ii
studying	study	vvg
substance	substance	nn1
abuse	abuse	nn1
and	and	cc
addiction	addiction	nn1
.	.	y
For	for	rex21
example	example	rex22
,	,	y
such	such	da
methods	method	nn2
as	as	csa
drug	drug	nn1
discrimination	discrimination	nn1
and	and	cc
drug	drug	nn1
self-administration	self-administration	nn1
have	have	vh0
become	become	vvn@
widely	widely	rr
used	use	vvn_vvd_jj
as	as	csa_ii@
tools	tool	nn2
in	in	ii
neurobiology	neurobiology	nn1
and	and	cc
neuroscience	neuroscience	nn1
research	research	nn1
on	on	ii
addiction	addiction	nn1
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2006	2006	mc
)	)	y
.	.	y
<p>	<p>	y
Behavioral	behavioral	jj
pharmacological	pharmacological	jj
understanding	understanding	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
and	and	cc
addiction	addiction	nn1
has	have	vhz
had	have	vhn
a	a	at1
significant	significant	jj
impact	impact	nn1
on	on	ii
clinical	clinical	jj
therapeutics	therapeutics	nn1
and	and	cc
clinical	clinical	jj
trials	trial	nn2
.	.	y
For	for	if
all	all	db
varieties	variety	nn2
of	of	io
addictive	addictive	jj
disorders	disorder	nn2
,	,	y
the	the	at
most	most	rgt
common	common	jj
treatment	treatment	nn1
is	be	vbz
counseling	counseling	nn1
based	base	vvn
on	on	ii
cognitive	cognitive	jj
behavioral	behavioral	jj_nn1
procedures	procedure	nn2
that	that	cst
emphasize	emphasize	vv0
the	the	at
risks	risk	nn2
posed	pose	vvn
by	by	ii
drug-related	drug-related	jj
environmental	environmental	jj
stimulus	stimulus	nn1
conditions	condition	nn2
,	,	y
the	the	at
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
and	and	cc
the	the	at
importance	importance	nn1
of	of	io
motivational	motivational	jj
or	or	cc
incentive-based	incentive-based	jj_nn1
approaches	approach	nn2_vvz
for	for	if
discouraging	discouraging	jj_vvg
drug	drug	nn1
use	use	nn1
and	and	cc
for	for	if
encouraging	encouraging	jj_vvg@
competing	competing	jj
alternative	alternative	jj_nn1
behaviors	behavior	nn2
.	.	y
This	this	dd1
type	type	nn1
of	of	io
cognitive-behavioral	cognitive-behavioral	jj_nn1
treatment	treatment	nn1
is	be	vbz
now	now	rt
widely	widely	rr
accepted	accept	vvn
as	as	ii_csa
the	the	at
appropriate	appropriate	jj
psychosocial	psychosocial	jj
treatment	treatment	nn1
platform	platform	nn1
for	for	if
conducting	conduct	vvg
clinical	clinical	jj
trials	trial	nn2
of	of	io
potential	potential	jj_nn1
pharmacotherapies		nn2
for	for	if
addictive	addictive	jj
disorders	disorder	nn2
(	(	y
Carroll	carroll	np1
&;		null
Onken	onken	np1
,	,	y
2005	2005	mc
)	)	y
.	.	y
<p>	<p>	y
Contingency	contingency	nn1
management	management	nn1
is	be	vbz
another	another	dd1
treatment	treatment	nn1
approach	approach	nn1_vv0@
that	that	cst_dd1
has	have	vhz
proven	prove	vvn
effective	effective	jj
for	for	if
reducing	reduce	vvg_jj@
drug	drug	nn1
use	use	nn1_vv0
across	across	ii
multiple	multiple	jj_nn1
substance	substance	nn1
use	use	nn1_vv0
disorders	disorder	nn2
.	.	y
This	this	dd1
approach	approach	nn1
capitalizes	capitalize	vvz
on	on	ii
the	the	at
stimulus-response	stimulus-response	jj_nn1
relationship	relationship	nn1
by	by	ii
using	use	vvg
clinically	clinically	rr
relevant	relevant	jj
reinforcers	reinforcer	nn2
to	to	to
increase	increase	vvi
the	the	at
rate	rate	nn1
of	of	io
desired	desired	jj@
behaviors	behavior	nn2
.	.	y
Early	early	jj
contingency	contingency	nn1
management	management	nn1
studies	study	nn2
conducted	conduct	vvn_vvd
with	with	iw
opioid	opioid	jj
addicts	addict	nn2
maintained	maintain	vvn_vvd
on	on	ii
methadone	methadone	nn1
demonstrated	demonstrate	vvd_vvn
that	that	cst
an	a	at1
array	array	nn1
of	of	io
reinforcers	reinforcer	nn2
,	,	y
such	such	ii21
as	as	ii22
small	small	jj
dose	dose	nn1
increases	increase	nn2_vvz
,	,	y
take-home	take-home	jj
doses	dose	nn2
,	,	y
and	and	cc
monetary	monetary	jj
payments	payment	nn2
,	,	y
could	could	vm
be	be	vbi
used	use	vvn
to	to	to
increase	increase	vvi
the	the	at
rate	rate	nn1
of	of	io
target	target	nn1
behaviors	behavior	nn2
,	,	y
including	including	ii_vvg@
drug	drug	nn1
abstinence	abstinence	nn1
,	,	y
attendance	attendance	nn1
,	,	y
and	and	cc
fee	fee	nn1
payments	payment	nn2
(	(	y
Stitzer	stitzer	np1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
&;		null
Liebson		np1
,	,	y
1979	1979	mc
,	,	y
1984	1984	mc
)	)	y
.	.	y
Alternatively	alternatively	rr
,	,	y
punishment	punishment	nn1
could	could	vm
be	be	vbi
used	use	vvn
(	(	y
e.g.	eg	rex
,	,	y
contingent	contingent	jj_nn1
dose	dose	nn1
decreases	decrease	vvz_nn2@
or	or	cc
treatment	treatment	nn1
termination	termination	nn1
)	)	y
to	to	to
suppress	suppress	vvi
undesired	undesired	jj
behaviors	behavior	nn2
(	(	y
e.g.	eg	rex
,	,	y
illicit	illicit	jj
drug	drug	nn1
use	use	nn1
)	)	y
(	(	y
Stitzer	stitzer	np1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
&;		null
Liebson		np1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
have	have	vh0
been	be	vbn
developed	develop	vvn
to	to	to
sustain	sustain	vvi
behaviors	behavior	nn2
by	by	ii
using	use	vvg
schedules	schedule	nn2
of	of	io
reinforcement	reinforcement	nn1
where	where	cs_rrq
the	the	at
magnitude	magnitude	nn1
of	of	io
reinforcer	reinforcer	nn1
(	(	y
i.e.	ie	rex
,	,	y
typically	typically	rr
money	money	nn1
or	or	cc
vouchers	voucher	nn2
exchangeable	exchangeable	jj
for	for	if
goods	good	nn2
and	and	cc
services	service	nn2
)	)	y
escalates	escalate	vvz
with	with	iw
repeated	repeated	jj@
desired	desired	jj@
responses	response	nn2
(	(	y
e.g.	eg	rex
,	,	y
consecutive	consecutive	jj
days	day	nnt2
of	of	io
abstinence	abstinence	nn1
)	)	y
(	(	y
Higgins	higgins	np1
,	,	y
Alessi	alessi	np1_nn1
,	,	y
&;		null
Dantona		np1
,	,	y
2002	2002	mc
)	)	y
.	.	y
The	the	at
contingency	contingency	nn1
management	management	nn1
voucher	voucher	nn1
procedures	procedure	nn2
have	have	vh0
demonstrated	demonstrate	vvn
efficacy	efficacy	nn1
across	across	ii
substance	substance	nn1
use	use	nn1_vv0
disorders	disorder	nn2
and	and	cc
treatment	treatment	nn1
environments	environment	nn2
,	,	y
which	which	ddq
has	have	vhz
led	lead	vvn
to	to	ii
their	their	appge
adoption	adoption	nn1
in	in	ii
clinical	clinical	jj
practice	practice	nn1
settings	setting	nn2
(	(	y
Stitzer	stitzer	np1
&;		null
Vandrey	vandrey	np1
,	,	y
2008	2008	mc
)	)	y
.	.	y
<p>	<p>	y
Another	another	dd1
creative	creative	jj
advance	advance	nn1
in	in	ii
the	the	at
field	field	nn1
has	have	vhz
been	be	vbn
the	the	at
application	application	nn1
of	of	io
economic	economic	jj
principles	principle	nn2
to	to	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
.	.	y
Behavioral	behavioral	jj_nn1
economics	economics	nn1
has	have	vhz
provided	provide	vvn
a	a	at1
theoretical	theoretical	jj
construct	construct	vv0_nn1%
to	to	to
understand	understand	vvi
the	the	at
relationship	relationship	nn1
of	of	io
data	data	nn
collected	collect	vvn_vvd
across	across	ii
different	different	jj
effective	effective	jj
procedures	procedure	nn2
on	on	ii
the	the	at
relative	relative	jj_nn1
reinforcing	reinforcing	jj@_vvg
efficacy	efficacy	nn1
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
.	.	y
By	by	ii
examining	examine	vvg
traditional	traditional	jj
outcome	outcome	nn1
measures	measure	nn2
,	,	y
such	such	ii21
as	as	ii22
response	response	nn1
rate	rate	nn1
,	,	y
as	as	csa_rg@
economic	economic	jj
indices	index	nn2
of	of	io
maximal	maximal	jj
output	output	nn1
and	and	cc
demand	demand	nn1_vv0
,	,	y
previously	previously	rr
disparate	disparate	jj
results	result	nn2
become	become	vv0
orderly	orderly	jj
and	and	cc
understandable	understandable	jj
as	as	ii_csa
a	a	at1
mathematical	mathematical	jj
function	function	nn1
within	within	ii
this	this	dd1
new	new	jj
framework	framework	nn1
(	(	y
Bickel	bickel	np1
,	,	y
Marsch	marsch	np1_nn1
,	,	y
&;		null
Carroll	carroll	np1
,	,	y
2000	2000	mc
)	)	y
.	.	y
Behavioral	behavioral	jj_nn1
economics	economics	nn1
has	have	vhz
also	also	rr
introduced	introduce	vvn
the	the	at
concept	concept	nn1
of	of	io
delay	delay	nn1
discounting	discounting	nn1_vvg
,	,	y
a	a	at1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
as	as	ii_csa
the	the	at
time	time	nnt1
to	to	ii
their	their	appge
anticipated	anticipated	jj
delivery	delivery	nn1
is	be	vbz
increased	increase	vvn_jj
(	(	y
Bickel	bickel	np1
&;		null
Marsch	marsch	np1
,	,	y
2001	2001	mc
)	)	y
.	.	y
Numerous	numerous	jj
studies	study	nn2
have	have	vh0
been	be	vbn
conducted	conduct	vvn
using	use	vvg
the	the	at
delay	delay	nn1
discounting	discounting	nn1_vvg
procedures	procedure	nn2
to	to	to
gain	gain	vvi
a	a	at1
better	better	jjr
understanding	understanding	nn1
of	of	io
how	how	rrq
changes	change	nn2
in	in	ii
reinforcer	reinforcer	nn1
magnitude	magnitude	nn1
and	and	cc
delay	delay	nn1
of	of	io
reinforcement	reinforcement	nn1
affect	affect	vv0_nn1
the	the	at
choice	choice	nn1
to	to	to
use	use	vvi
drugs	drug	nn2
.	.	y
Individual	individual	jj_nn1
differences	difference	nn2
in	in	ii
delay-discounting	delay-discounting	jj_nn1
behavior	behavior	nn1
have	have	vh0
been	be	vbn
used	use	vvn
as	as	ii
an	a	at1
experimental	experimental	jj
proxy	proxy	nn1
for	for	if
impulsivity--providing	impulsivity--providing	nn1_jj
a	a	at1
quantitative	quantitative	jj
framework	framework	nn1
for	for	if
measurement	measurement	nn1
of	of	io
choice	choice	nn1_jj@
behavior	behavior	nn1
as	as	ii_csa
a	a	at1
function	function	nn1
of	of	io
a	a	at1
preexisting	pre-existing	jj@_nn1@
personality	personality	nn1
trait	trait	nn1
.	.	y
<p>	<p>	y
The	the	at
importance	importance	nn1
and	and	cc
contributions	contribution	nn2
of	of	io
behavioral	behavioral	jj
pharmacological	pharmacological	jj
science	science	nn1
are	be	vbr
also	also	rr
reflected	reflect	vvn_vvd
in	in	ii
our	our	appge
national	national	jj
history	history	nn1
with	with	iw
tobacco	tobacco	nn1
over	over	ii
the	the	at
past	past	jj_nn1
few	few	da2
decades	decade	nnt2
.	.	y
The	the	at
1988	1988	mc
Surgeon	surgeon	nn1
General	general	nn1
's	's	ge
Report	report	nn1
on	on	ii
Tobacco	tobacco	nn1
Addiction	addiction	npx
(	(	y
USDHEW		np1_vv0_nn1
,	,	y
1988	1988	mc
)	)	y
,	,	y
followed	follow	vvn
by	by	ii
more	more	rgr_dar
recent	recent	jj
revelations	revelation	nn2
that	that	cst
the	the	at
tobacco	tobacco	nn1
industry	industry	nn1
understood	understand	vvd_vvn
the	the	at
addictive	addictive	jj
characteristics	characteristic	nn2
of	of	io
tobacco	tobacco	nn1
,	,	y
and	and	cc
used	used	jj_vvd
marketing	marketing	nn1
to	to	to
promote	promote	vvi
addiction	addiction	nn1
while	while	cs
publicly	publicly	rr
denying	deny	vvg
that	that	cst
this	this	dd1
was	be	vbdz
the	the	at
case	case	nn1
,	,	y
transformed	transform	vvd_vvn
our	our	appge
national	national	jj
tobacco	tobacco	nn1
policy	policy	nn1
.	.	y
This	this	dd1
transformation	transformation	nn1
was	be	vbdz
built	build	vvn
on	on	ii
a	a	at1
foundation	foundation	nn1
of	of	io
behavioral	behavioral	jj
pharmacological	pharmacological	jj
research	research	nn1
on	on	ii
tobacco	tobacco	nn1
and	and	cc
tobacco	tobacco	nn1
dependence	dependence	nn1
(	(	y
Henningfield	henningfield	np1
&;		null
Fant	fant	np1
,	,	y
1999	1999	mc
)	)	y
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
CHALLENGES	challenge	nn2
AND	and	cc
OPPORTUNITIES	opportunity	nn2
FOR	for	if
BEHAVIORAL	behavioral	jj_np1
PHARMACOLOGY	pharmacology	nn1_np1
RESEARCH	research	nn1
IN	in	ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
drug	drug	nn1
use	use	nn1_vv0
well	well	rr_nn1@
,	,	y
but	but	ccb
falls	fall	vvz
short	short	jj_rr@
of	of	io
defining	define	vvg
pathological	pathological	jj
forms	form	nn2
of	of	io
drug	drug	nn1
abuse	abuse	nn1
.	.	y
This	this	dd1
challenge	challenge	nn1
comes	come	vvz
from	from	ii
the	the	at
view	view	nn1
that	that	cst
some	some	dd
qualitative	qualitative	jj
difference	difference	nn1
exists	exist	vvz
between	between	ii
the	the	at
principles	principle	nn2
that	that	cst
apply	apply	vv0
to	to	to
use	use	vvi
and	and	cc
abuse	abuse	nn1
(	(	y
i.e.	ie	rex
,	,	y
that	that	cst
a	a	at1
"	"	y
switch	switch	nn1
"	"	y
exists	exist	vvz
that	that	cst
results	result	nn2_vvz@
in	in	ii
drug	drug	nn1
abuse	abuse	nn1
disorders	disorder	nn2
)	)	y
.	.	y
Various	various	jj
lines	line	nn2
of	of	io
investigation	investigation	nn1
have	have	vh0
been	be	vbn
developed	develop	vvn
to	to	to
address	address	vvi
this	this	dd1
concern	concern	nn1
,	,	y
many	many	da2
of	of	io
which	which	ddq
incorporate	incorporate	vv0
brain	brain	nn1
biology	biology	nn1
into	into	ii
a	a	at1
more	more	rgr
comprehensive	comprehensive	jj
theory	theory	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
(	(	y
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2006	2006	mc
)	)	y
.	.	y
These	these	dd2
lines	line	nn2
of	of	io
investigation	investigation	nn1
also	also	rr
incorporate	incorporate	vv0
measures	measure	nn2
of	of	io
mood	mood	nn1
(	(	y
e.g.	eg	rex
,	,	y
hedonic	hedonic	jj
dysregulation	dysregulation	nn1
)	)	y
,	,	y
cognitive	cognitive	jj
processing	processing	nn1
(	(	y
e.g.	eg	rex
,	,	y
craving	crave	vvg
)	)	y
,	,	y
and	and	cc
the	the	at
role	role	nn1
of	of	io
character	character	nn1
traits	trait	nn2
(	(	y
e.g.	eg	rex
,	,	y
risk-taking	risk-taking	jj_nn1
or	or	cc
impulsivity	impulsivity	nn1
)	)	y
.	.	y
It	it	pph1
is	be	vbz
too	too	rg
soon	soon	rr
to	to	to
know	know	vvi
if	if	csw@_cs
this	this	dd1
variation	variation	nn1
on	on	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
will	will	vm
yield	yield	vvi
insights	insight	nn2
into	into	ii
addiction	addiction	nn1
that	that	cst_dd1
will	will	vm
result	result	vvi
in	in	ii
novel	novel	jj_nn1
therapies	therapy	nn2
.	.	y
From	from	ii
the	the	at
perspective	perspective	nn1
of	of	io
animal	animal	nn1
research	research	nn1
,	,	y
much	much	da1_rr
research	research	nn1_vv0@
on	on	ii
the	the	at
development	development	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
has	have	vhz
reverted	revert	vvn
to	to	ii
indirect	indirect	jj
measures	measure	nn2
of	of	io
abuse-related	abuse-related	jj_nn1
phenomena	phenomenon	nn2
,	,	y
such	such	ii21
as	as	ii22
sensitization	sensitization	nn1
of	of	io
locomotor	locomotor	nn1
behavior	behavior	nn1
(	(	y
Nelson	nelson	np1
&;		null
Kilcross		np1
,	,	y
2006	2006	mc
;	;	y
Robinson	robinson	np1
&;		null
Berridge	berridge	np1
,	,	y
1993	1993	mc
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
2007	2007	mc
;	;	y
Koob	koob	np1
,	,	y
1992	1992	mc
)	)	y
.	.	y
Perhaps	perhaps	rr
an	a	at1
important	important	jj
direction	direction	nn1
would	would	vm
be	be	vbi
to	to	to
retain	retain	vvi
the	the	at
complexity	complexity	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
models	model	nn2
of	of	io
addiction	addiction	nn1
while	while	cs
looking	look	vvg
for	for	if
systematic	systematic	jj
qualitative	qualitative	jj
changes	change	nn2
in	in	ii
behaviors	behavior	nn2
that	that	cst
reflect	reflect	vv0
the	the	at
addiction	addiction	nn1
process	process	nn1
.	.	y
In	in	rr21
addition	addition	rr22
,	,	y
developing	developing	jj_vvg
animal	animal	nn1
models	model	nn2
for	for	if
the	the	at
reinstatement	reinstatement	nn1
of	of	io
drug	drug	nn1
self-administration	self-administration	nn1
holds	hold	vvz
great	great	jj
promise	promise	nn1
for	for	if
studying	study	vvg
relapse	relapse	nn1
(	(	y
Shaham	shaham	np1
,	,	y
Shalev	shalev	np1
,	,	y
Lu	lu	np1_nn1
,	,	y
De	de	np1
Wit	wit	nn1
,	,	y
&;		null
Stewarti		np1_nn1_jj
2003	2003	mc
)	)	y
.	.	y
It	it	pph1
should	should	vm
be	be	vbi
noted	note	vvn
that	that	cst
one	one	mc1
of	of	io
the	the	at
symptoms	symptom	nn2
of	of	io
drug	drug	nn1
abuse	abuse	nn1_vv0@
that	that	cst_dd1
drives	drive	vvz
this	this	dd1
concept	concept	nn1
of	of	io
a	a	at1
disease	disease	nn1
process	process	nn1
is	be	vbz
self-control	self-control	nn1
.	.	y
Addicts	addict	nn2
are	be	vbr
often	often	rr
described	describe	vvn
as	as	csa
out	out	ii21
of	of	ii22
control	control	nn1
and	and	cc
compulsive	compulsive	jj
.	.	y
Indeed	indeed	rr
,	,	y
psychiatric	psychiatric	jj
criteria	criteria	nn2
for	for	if
diagnosis	diagnosis	nn1
of	of	io
drug	drug	nn1
dependence	dependence	nn1
,	,	y
as	as	ii31
opposed	opposed	ii32
to	to	ii33
drug	drug	nn1
abuse	abuse	nn1
,	,	y
tend	tend	vv0
to	to	to
rely	rely	vvi
on	on	ii
endorsement	endorsement	nn1
of	of	io
specific	specific	jj
symptoms	symptom	nn2
or	or	cc
behaviors	behavior	nn2
related	relate	vvn_vvd
to	to	ii
the	the	at
loss	loss	nn1
of	of	io
control	control	nn1
,	,	y
such	such	ii21
as	as	ii22
"	"	y
a	a	at1
persistent	persistent	jj
desire	desire	nn1
or	or	cc
unsuccessful	unsuccessful	jj
efforts	effort	nn2
to	to	to
cut	cut	vvi
down	down	rp
or	or	cc
control	control	nn1_vv0
substance	substance	nn1
use	use	nn1
"	"	y
(	(	y
American	american	jj
Psychiatric	psychiatric	jj
Association	association	nn1
,	,	y
2000	2000	mc
,	,	y
p.	xx_p	nn1_nnu
197	197	mc
)	)	y
.	.	y
Behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
challenges	challenge	vvz@_nn2
this	this	dd1
concept	concept	nn1
.	.	y
Most	most	dat
research	research	nn1
shows	show	vvz
that	that	cst
even	even	rr
the	the	at
most	most	rgt
pathological	pathological	jj
forms	form	nn2
of	of	io
drug-taking	drug-taking	nn1
behavior	behavior	nn1
in	in	ii
animals	animal	nn2
and	and	cc
humans	human	nn2
is	be	vbz
actually	actually	rr
well-controlled	well-controlled	jj_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Bickel	bickel	np1
&;		null
Marsch	marsch	np1
,	,	y
2001	2001	mc
;	;	y
Higgins	higgins	np1
,	,	y
Bickel	bickel	np1
,	,	y
&;		null
Hughes	hughes	np1
,	,	y
1994	1994	mc
)	)	y
,	,	y
just	just	rr
not	not	xx
by	by	ii
the	the	at
most	most	rgt
desirable	desirable	jj
variables	variable	nn2
.	.	y
For	for	rex21
example	example	rex22
,	,	y
even	even	rr
modest	modest	jj
payments	payment	nn2
for	for	if
clean	clean	jj
urine	urine	nn1
samples	sample	nn2
can	can	vm
result	result	vvi
in	in	ii
considerable	considerable	jj
behavioral	behavioral	jj_nn1
changes	change	nn2
in	in	ii
individuals	individual	nn2
with	with	iw
severe	severe	jj
drug	drug	nn1
abuse	abuse	nn1
problems	problem	nn2
(	(	y
Petry	petry	np1
&;		null
Martin	martin	np1
,	,	y
2002	2002	mc
)	)	y
.	.	y
<p>	<p>	y
Behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
has	have	vhz
not	not	xx
fully	fully	rr
explored	explore	vvn
genetics	genetics	nn1
.	.	y
Behavioral	behavioral	jj_nn1
psychology	psychology	nn1
and	and	cc
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
have	have	vh0
tended	tend	vvn
to	to	to
minimize	minimize	vvi
the	the	at
roles	role	nn2
of	of	io
genetics	genetics	nn1
and	and	cc
inherited	inherit	vvd_vvn_jj@
individual	individual	jj
differences	difference	nn2
.	.	y
In	in	rr21
general	general	rr22
,	,	y
the	the	at
behavioral	behavioral	jj_nn1
view	view	nn1
of	of	io
addiction	addiction	nn1
has	have	vhz
been	be	vbn
far	far	rr_jj
onto	onto	ii
the	the	at
"	"	y
nurture	nurture	nn1
"	"	y
end	end	nn1
of	of	io
the	the	at
nature-nurture	nature-nurture	jj
continuum	continuum	nn1
,	,	y
taking	take	vvg
the	the	at
view	view	nn1
that	that	cst_dd1
vulnerability	vulnerability	nn1
to	to	ii
addiction	addiction	nn1
is	be	vbz
universal	universal	jj
and	and	cc
that	that	cst
the	the	at
major	major	jj
determinants	determinant	nn2
of	of	io
addictive	addictive	jj
behavior	behavior	nn1
lie	lie	vv0_nn1@
in	in	ii_rp@
environmental	environmental	jj
conditions	condition	nn2
and	and	cc
in	in	ii
experiential	experiential	jj
learning	learning	nn1
.	.	y
However	however	rr
,	,	y
extensive	extensive	jj
data--both	data--both	rr
animal	animal	nn1_jj%
and	and	cc
human--make	human--make	jj
clear	clear	jj
that	that	cst_dd1
genetics	genetics	nn1
play	play	vv0_nn1
an	a	at1
important	important	jj
role	role	nn1
in	in	ii
addiction	addiction	nn1
vulnerability	vulnerability	nn1
and	and	cc
risk	risk	nn1_vv0
(	(	y
Belknap	belknap	np1_vv0_nn1
,	,	y
Metten		np1_vv0
,	,	y
Beckley	beckley	np1
,	,	y
&;		null
Crabbe	crabbe	np1
,	,	y
2008	2008	mc
;	;	y
Kreek		np1
,	,	y
Nielsen	nielsen	np1
,	,	y
&;		null
LaForge	laforge	np1_vv0_nn1
,	,	y
2004	2004	mc
;	;	y
Uhl	uhl	np1
,	,	y
2004	2004	mc
)	)	y
.	.	y
The	the	at
need	need	nn1
for	for	if
high	high	jj
throughput	throughput	nn1
phenotyping		vvg
for	for	if
behavioral	behavioral	jj_nn1
genetics	genetics	nn1
research	research	nn1
has	have	vhz
led	lead	vvn
to	to	ii
some	some	dd
abandonment	abandonment	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
implications	implication	nn2
of	of	io
this	this	dd1
backward	backward	jj
step	step	nn1
in	in	ii
animal	animal	nn1
modeling	modeling	nn1
have	have	vh0
yet	yet	rr
to	to	to
be	be	vbi
determined	determine	vvn
.	.	y
A	a	at1_zz1
similar	similar	jj
problem	problem	nn1
exists	exist	vvz
for	for	if
defining	define	vvg_jj@
phenotypes	phenotype	nn2
for	for	if
genetic	genetic	jj
studies	study	nn2
in	in	ii
humans	human	nn2
.	.	y
Measured	measured	jj@_vvn
patterns	pattern	nn2
of	of	io
behavior	behavior	nn1
are	be	vbr
rarely	rarely	rr
used	use	vvn_vvd_jj
.	.	y
Instead	instead	rr
,	,	y
phenotypes	phenotype	nn2
derived	derive	vvn
from	from	ii
epidemiology	epidemiology	nn1
,	,	y
such	such	ii21
as	as	ii22
"	"	y
ever	ever	rr
used	use	vvn_jj_vvd
"	"	y
or	or	cc
meeting	meet	vvg
a	a	at1
diagnostic	diagnostic	jj
criterion	criteria	nn1
for	for	if
dependence	dependence	nn1
,	,	y
dominate	dominate	vv0
this	this	dd1
field	field	nn1
.	.	y
Again	again	rt
,	,	y
the	the	at
problem	problem	nn1
is	be	vbz
,	,	y
in	in	rr21
part	part	rr22
,	,	y
the	the	at
result	result	nn1
of	of	io
the	the	at
large	large	jj
numbers	number	nn2
of	of	io
subjects	subject	nn2
needed	need	vvn_vvd
for	for	if
association	association	nn1
and	and	cc
linkage	linkage	nn1
studies	study	nn2
,	,	y
making	make	vvg
careful	careful	jj
measurement	measurement	nn1
of	of	io
behavior	behavior	nn1
impractical	impractical	jj
.	.	y
We	we	ppis2
are	be	vbr
at	at	ii
the	the	at
early	early	jj
stages	stage	nn2
of	of	io
learning	learn	vvg
the	the	at
role	role	nn1
genes	gene	nn2
play	play	vv0
in	in	ii_rp@
addiction	addiction	nn1
,	,	y
and	and	cc
the	the	at
full	full	jj
story	story	nn1
is	be	vbz
likely	likely	jj
to	to	to
be	be	vbi
quite	quite	rg
complex	complex	jj
.	.	y
It	it	pph1
appears	appear	vvz
some	some	dd
genetic	genetic	jj
risk	risk	nn1
factors	factor	nn2
are	be	vbr
drug-specific	drug-specific	jj
(	(	y
i.e.	ie	rex
,	,	y
opioid	opioid	nn1_jj
versus	versus	ii
alcohol	alcohol	nn1
versus	versus	ii
tobacco	tobacco	nn1
dependence	dependence	nn1
)	)	y
and	and	cc
some	some	dd
non-specific	non-specific	jj
(	(	y
i.e.	ie	rex
,	,	y
perhaps	perhaps	rr
more	more	rrr_dar
like	like	ii
a	a	at1
personality-related	personality-related	jj_nn1
vulnerability	vulnerability	nn1
factor	factor	nn1
)	)	y
.	.	y
It	it	pph1
also	also	rr
appears	appear	vvz
that	that	cst
separate	separate	vv0_jj
genetic	genetic	jj
risk	risk	nn1
factors	factor	nn2
may	may	vm
be	be	vbi
related	relate	vvn
to	to	ii
the	the	at
initiation	initiation	nn1
of	of	io
substance	substance	nn1
use	use	nn1_vv0
experimentation	experimentation	nn1
versus	versus	ii
the	the	at
progression	progression	nn1
from	from	ii
use	use	nn1
to	to	ii
abuse	abuse	nn1
and	and	cc
dependence	dependence	nn1
.	.	y
We	we	ppis2
also	also	rr
know	know	vv0
that	that	cst
many	many	da2
individuals	individual	nn2
initiate	initiate	vv0
use	use	nn1_vv0
and	and	cc
progress	progress	nn1_vv0@
to	to	ii
addiction	addiction	nn1
without	without	iw
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
concept	concept	nn1
of	of	io
universal	universal	jj
vulnerability	vulnerability	nn1
)	)	y
.	.	y
The	the	at
challenge	challenge	nn1
for	for	if
the	the	at
future	future	nn1
is	be	vbz
to	to	to
learn	learn	vvi
much	much	da1_rr
more	more	dar_rrr
about	about	ii
this	this	dd1
genetic	genetic	jj
diversity	diversity	nn1
and	and	cc
,	,	y
most	most	rgt
importantly	importantly	rr
,	,	y
to	to	to
learn	learn	vvi
how	how	rrq
it	it	pph1
can	can	vm
be	be	vbi
made	make	vvn
relevant	relevant	jj
and	and	cc
useful	useful	jj
to	to	ii
the	the	at
tasks	task	nn2
of	of	io
preventing	prevent	vvg
and	and	cc
treating	treat	vvg
substance	substance	nn1
abuse	abuse	nn1
.	.	y
We	we	ppis2
have	have	vh0
yet	yet	rr
to	to	to
see	see	vvi
whether	whether	csw
the	the	at
specific	specific	jj
nature	nature	nn1
of	of	io
individuals	individual	nn2
'	'	ge
genetic	genetic	jj
vulnerability	vulnerability	nn1
profile	profile	nn1
can	can	vm
be	be	vbi
used	use	vvn
to	to	to
guide	guide	vvi
the	the	at
development	development	nn1
or	or	cc
selection	selection	nn1
of	of	io
pharmacotherapy	pharmacotherapy	nn1
,	,	y
and	and	cc
whether	whether	csw
different	different	jj
pharmacotherapies		nn2
might	might	vm
be	be	vbi
specific	specific	jj
to	to	ii
or	or	cc
have	have	vh0
differential	differential	jj
effectiveness	effectiveness	nn1
in	in	ii
different	different	jj
individuals	individual	nn2
.	.	y
The	the	at
continuing	continuing	jj
exploration	exploration	nn1
of	of	io
genetic	genetic	jj
risk	risk	nn1
factors	factor	nn2
will	will	vm
be	be	vbi
most	most	rgt
useful	useful	jj
if	if	cs_csw@
it	it	pph1
can	can	vm
move	move	vvi
beyond	beyond	ii
identifying	identify	vvg
increased	increased	jj
risk	risk	nn1
and	and	cc
begin	begin	vvi
guiding	guiding	jj
therapy	therapy	nn1
development	development	nn1
and	and	cc
individualized	individualized	jj@_vvd
therapy	therapy	nn1
selection	selection	nn1
.	.	y
<p>	<p>	y
The	the	at
developmental	developmental	jj
aspect	aspect	nn1
of	of	io
substance	substance	nn1
use	use	nn1_vv0
disorders	disorder	nn2
is	be	vbz
another	another	dd1
problem	problem	nn1
area	area	nn1
for	for	if
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
.	.	y
Age-related	age-related	jj_nn1
variables	variable	nn2
do	do	vd0
play	play	vvi
a	a	at1
very	very	rg
significant	significant	jj
role	role	nn1
in	in	ii
the	the	at
development	development	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
,	,	y
yet	yet	rr
very	very	rg
few	few	da2
investigators	investigator	nn2
have	have	vh0
taken	take	vvn
a	a	at1
developmental	developmental	jj
approach	approach	nn1
.	.	y
Much	much	da1
of	of	io
the	the	at
field	field	nn1
is	be	vbz
based	base	vvn
on	on	ii
studies	study	nn2
with	with	iw
adults	adult	nn2
,	,	y
especially	especially	rr
adult	adult	jj@_nn1
males	male	nn2
,	,	y
although	although	cs
we	we	ppis2
know	know	vv0
that	that	dd1_cst
adolescence	adolescence	nn1
is	be	vbz
a	a	at1
critical	critical	jj
period	period	nn1
for	for	if
the	the	at
development	development	nn1
of	of	io
drug	drug	nn1
use	use	nn1_vv0
disorders	disorder	nn2
.	.	y
More	more	rgr_rrr
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
However	however	rr
,	,	y
these	these	dd2
are	be	vbr
methodologically	methodologically	rr
challenging	challenge	vvg
in	in	rp@_ii
both	both	rr
animals	animal	nn2
and	and	cc
humans	human	nn2
.	.	y
In	in	ii
the	the	at
preclinical	preclinical	jj
laboratories	laboratory	nn2
,	,	y
most	most	dat
of	of	io
this	this	dd1
work	work	nn1
is	be	vbz
conducted	conduct	vvn
in	in	ii
rodent	rodent	nn1
models	model	nn2
where	where	rrq_cs
the	the	at
developmental	developmental	jj
period	period	nn1
of	of	io
adolescence	adolescence	nn1
is	be	vbz
very	very	rg
brief	brief	jj
,	,	y
thus	thus	rr
allowing	allow	vvg
only	only	rr
a	a	at1
limited	limited	jj
window	window	nn1
of	of	io
opportunity	opportunity	nn1
for	for	if
study	study	nn1
.	.	y
In	in	ii
the	the	at
clinical	clinical	jj
field	field	nn1
,	,	y
observational	observational	jj
or	or	cc
qualitative	qualitative	jj
studies	study	nn2
are	be	vbr
more	more	rgr
common	common	jj
than	than	csn
interventional	interventional	jj
studies	study	nn2
because	because	cs
research	research	nn1
with	with	iw
vulnerable	vulnerable	jj
adolescents	adolescent	nn2
can	can	vm
raise	raise	vvi
special	special	jj
ethical	ethical	jj
and	and	cc
regulatory	regulatory	jj
hurdles	hurdle	nn2
.	.	y
<p>	<p>	y
In	in	ii
two	two	mc
areas	area	nn2
,	,	y
expansion	expansion	nn1
of	of	io
the	the	at
methodological	methodological	jj
approach	approach	nn1
in	in	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
may	may	vm
be	be	vbi
challenging	challenging	jj_vvg
,	,	y
but	but	ccb
potentially	potentially	rr
fruitful	fruitful	jj
.	.	y
The	the	at
first	first	md
is	be	vbz
the	the	at
application	application	nn1
of	of	io
multivariate	multivariate	jj
approaches	approach	nn2
.	.	y
Behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
comes	come	vvz
:	:	y
from	from	ii
a	a	at1
strong	strong	jj
tradition	tradition	nn1
in	in	ii
both	both	db2_rr
behavioral	behavioral	jj
sciences	science	nn2
and	and	cc
pharmacology	pharmacology	nn1
of	of	io
single	single	jj
variable	variable	nn1_jj
manipulations	manipulation	nn2
in	in	ii_rp@
highly	highly	rr
controlled	control	vvn_vvd_jj@
settings	setting	nn2
.	.	y
This	this	dd1
bears	bear	vvz
little	little	jj
resemblances	resemblance	nn2
to	to	ii
real	real	jj
life	life	nn1
.	.	y
Behavioral	behavioral	jj_nn1
pharmacologists	pharmacologist	nn2
use	use	vv0
experimental	experimental	jj
designs	design	nn2
and	and	cc
often	often	rr
use	use	vv0
univariate	univariate	vv0_nn1
statistical	statistical	jj
procedures	procedure	nn2
that	that	cst
have	have	vh0
been	be	vbn
in	in	ii
existence	existence	nn1
for	for	if
over	over	rg
50	50	mc
years	year	nnt2
and	and	cc
have	have	vh0
not	not	xx
fully	fully	rr
incorporated	incorporate	vvn
important	important	jj
developments	development	nn2
in	in	ii
multivariate	multivariate	jj
methods	method	nn2
and	and	cc
longitudinal	longitudinal	jj
research	research	nn1
(	(	y
Collins	collins	np1
&;		null
Sayer	sayer	np1
,	,	y
2001	2001	mc
)	)	y
.	.	y
The	the	at
second	second	md
methodological	methodological	jj
challenge	challenge	nn1
arises	arise	vvz
from	from	ii
the	the	at
emergence	emergence	nn1
of	of	io
the	the	at
field	field	nn1
of	of	io
molecular	molecular	jj
biology	biology	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Koob	koob	np1
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
2006	2006	mc
;	;	y
Madras	madras	np1
et	et	ra21
al.	al	ra22
,	,	y
2006	2006	mc
)	)	y
.	.	y
While	while	cs
some	some	dd
very	very	rg
useful	useful	jj
multidisciplinary	multidisciplinary	jj_nn1
work	work	nn1
has	have	vhz
been	be	vbn
done	do	vdn
in	in	ii
this	this	dd1
area	area	nn1
,	,	y
some	some	dd
new	new	jj
approaches	approach	nn2
are	be	vbr
probably	probably	rr
needed	need	vvn_vvd
.	.	y
For	for	rex21
example	example	rex22
,	,	y
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
traditionally	traditionally	rr
uses	use	vvz
within-subject	within-subject	nn1_jj@
designs	design	nn2
,	,	y
whereas	whereas	cs
genetically-altered	genetically-altered	jj
animals	animal	nn2
typically	typically	rr
require	require	vv0
group	group	nn1
designs	design	nn2
.	.	y
<p>	<p>	y
An	a	at1
area	area	nn1
of	of	io
opportunity	opportunity	nn1
for	for	if
future	future	jj_nn1
research	research	nn1
is	be	vbz
the	the	at
question	question	nn1
of	of	io
the	the	at
extent	extent	nn1
of	of	io
pharmacological	pharmacological	jj
specificity	specificity	nn1
of	of	io
various	various	jj
procedures	procedure	nn2
,	,	y
mechanisms	mechanism	nn2
,	,	y
and	and	cc
interventions	intervention	nn2
across	across	ii
different	different	jj
forms	form	nn2
of	of	io
substance	substance	nn1
abuse	abuse	nn1
.	.	y
From	from	ii
the	the	at
pharmacological	pharmacological	jj
perspective	perspective	nn1
,	,	y
we	we	ppis2
tend	tend	vv0
to	to	to
think	think	vvi
of	of	io
different	different	jj
types	type	nn2
of	of	io
substance	substance	nn1
abuse	abuse	nn1
as	as	csa
being	be	vbg
very	very	rg
distinct	distinct	jj
and	and	cc
involving	involve	vvg
quite	quite	rg
different	different	jj
neuropharmacological	neuropharmacological	jj
mechanisms	mechanism	nn2
,	,	y
and	and	cc
we	we	ppis2
tend	tend	vv0
to	to	to
expect	expect	vvi
that	that	cst
pharmacotherapies		nn2
will	will	vm
likely	likely	rr@
have	have	vhi
a	a	at1
fairly	fairly	rr
narrow	narrow	jj
pharmacological	pharmacological	jj
specificity	specificity	nn1
for	for	if
a	a	at1
particular	particular	jj
type	type	nn1
of	of	io
substance	substance	nn1
abuse	abuse	nn1
.	.	y
However	however	rr
,	,	y
to	to	ii
the	the	at
extent	extent	nn1
that	that	cst_dd1
different	different	jj
varieties	variety	nn2
of	of	io
substance	substance	nn1
abuse	abuse	nn1
may	may	vm
involve	involve	vvi
common	common	jj
,	,	y
nonspecific	non-specific	jj
vulnerability	vulnerability	nn1
factors	factor	nn2
,	,	y
or	or	cc
may	may	vm
involve	involve	vvi
common	common	jj
neurocognitive	neurocognitive	jj
or	or	cc
affective	affective	jj
elements	element	nn2
,	,	y
or	or	cc
,	,	y
finally	finally	rr
,	,	y
may	may	vm
share	share	vvi
final	final	jj
common	common	jj
pathways	pathway	nn2
,	,	y
we	we	ppis2
may	may	vm
discover	discover	vvi
nonspecific	non-specific	jj
pharmacological	pharmacological	jj
treatments	treatment	nn2
with	with	iw
efficacy	efficacy	nn1
across	across	ii_rl@
pharmacologically	pharmacologically	rr
different	different	jj
forms	form	nn2
of	of	io
substance	substance	nn1
abuse	abuse	nn1
.	.	y
Learning	learn	vvg_nn1
more	more	rrr_dar
about	about	ii
the	the	at
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
great	great	jj
impact	impact	nn1
in	in	ii
the	the	at
future	future	nn1_jj
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
AUTHOR	author	nn1
REFLECTIONS	reflection	nn2
ROBERT	robert	np1
BALSTER	balster	nn1
<p>	<p>	y
I	i	ppis1
was	be	vbdz
fortunate	fortunate	jj
to	to	to
be	be	vbi
among	among	ii
the	the	at
second	second	nnt1_md
to	to	ii
third	third	md
generation	generation	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacologists	pharmacologist	nn2
.	.	y
I	i	ppis1
did	do	vdd
my	my	appge
graduate	graduate	nn1
work	work	vvi
in	in	ii
the	the	at
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
laboratories	laboratory	nn2
of	of	io
Robert	robert	np1
T.	t	np1
Harris	harris	np1
,	,	y
obtaining	obtain	vvg
my	my	appge
Ph.D	phd	np1
.	.	y
in	in	ii
Psychology	psychology	nn1
from	from	ii
the	the	at
University	university	nn1
of	of	io
Houston	houston	np1
.	.	y
My	my	appge
graduate	graduate	nn1
work	work	nn1
was	be	vbdz
on	on	ii
drug	drug	nn1
discrimination	discrimination	nn1
where	where	cs_rrq
Bob	bob	np1
Harris	harris	np1
and	and	cc
I	i	ppis1
demonstrated	demonstrate	vvd
that	that	dd1_cst
amphetamine	amphetamine	nn1_vv0
could	could	vm
lower	lower	vvi
rates	rate	nn2
of	of	io
behavior	behavior	nn1
if	if	cs
animals	animal	nn2
were	be	vbdr
trained	train	vvn
to	to	to
respond	respond	vvi
slowly	slowly	rr
in	in	ii
its	its	z'
presence	presence	nn1
and	and	cc
rapidly	rapidly	rr
with	with	iw
placebo	placebo	nn1
(	(	y
Harris	harris	np1
&;		null
Balster	balster	np1
,	,	y
1968	1968	mc
)	)	y
.	.	y
The	the	at
work	work	nn1
I	i	ppis1
did	do	vdd
with	with	iw
Bob	bob	np1
Harris	harris	np1
is	be	vbz
included	include	vvn
in	in	ii
Pickens	pickens	np1_nn2
and	and	cc
Thompson	thompson	np1
(	(	y
1970	1970	mc
)	)	y
<p>	<p>	y
STIMULUS	stimulus	npx
PROPERTIES	property	nn2
OF	of	io
DRUGS	drug	nn2
.	.	y
<p>	<p>	y
In	in	ii
1970	1970	mc
,	,	y
I	i	ppis1
went	go	vvd
on	on	rp_ii21
to	to	ii_ii22
the	the	at
laboratories	laboratory	nn2
of	of	io
Charles	charles	np1
R.	xx_r	np1
Schuster	schuster	np1_nn1
to	to	to
do	do	vdi
a	a	at1
postdoctoral	postdoctoral	jj_nn1
fellowship	fellowship	nn1
.	.	y
Other	other	jj
trainees	trainee	nn2
there	there	rl
at	at	ii
the	the	at
time	time	nnt1
included	include	vvd_vvn
Chris-Ellyn		np1
Johanson	johanson	np1
,	,	y
Marian	marian	np1
Fischman	fischman	np1
,	,	y
Linda	linda	np1
Dykstra	dykstra	np1
,	,	y
and	and	cc
Klaus	klaus	np1
Miczek	miczek	np1
,	,	y
all	all	db
of	of	io
whom	whom	pnqo
emerged	emerge	vvd
as	as	rg@_csa
important	important	jj
leaders	leader	nn2
in	in	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
.	.	y
While	while	cs
working	work	vvg
with	with	iw
Dr.	dr	nnb
Schuster	schuster	np1
,	,	y
I	i	ppis1
published	publish	vvd
several	several	da2
studies	study	nn2
of	of	io
drug	drug	nn1
self-administration	self-administration	nn1
using	use	vvg
rhesus	rhesus	nn1
monkeys	monkey	nn2
.	.	y
It	it	pph1
was	be	vbdz
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
solidified	solidify	vvd
,	,	y
fostered	foster	vvn
by	by	ii
meetings	meeting	nn2
of	of	io
the	the	at
Committee	committee	nn1
on	on	ii
Problems	problem	nn2
of	of	io
Drug	drug	nn1
Dependence	dependence	nn1
(	(	y
CPDD	cpdd	np1
)	)	y
and	and	cc
the	the	at
Division	division	nn1
of	of	io
Psychopharmacology	psychopharmacology	nn1
of	of	io
the	the	at
American	american	jj
Psychological	psychological	jj
Association	association	nn1
.	.	y
Another	another	dd1
important	important	jj
organization	organization	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacologists	pharmacologist	nn2
working	work	vvg
in	in	ii
the	the	at
area	area	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
is	be	vbz
the	the	at
International	international	jj
Study	study	nn1
Group	group	nn1
Investigating	investigate	vvg
Drugs	drug	nn2
as	as	csa_ii@
Reinforcers		np1_nn2
(	(	y
ISGIDAR		np1
)	)	y
.	.	y
Of	of	io
particular	particular	jj
importance	importance	nn1
to	to	ii
me	me	ppio1
as	as	ii
a	a	at1
young	young	jj
scientist	scientist	nn1
was	be	vbdz
that	that	cst
Dr.	dr	nnb
Schuster	schuster	np1
enlisted	enlist	vvd
Chris-Ellyn		np1
Johanson	johanson	np1
and	and	cc
me	me	ppio1
to	to	to
organize	organize	vvi
a	a	at1
multi-laboratory	multi-laboratory	jj_nn1
validation	validation	nn1
effort	effort	nn1
for	for	if
ISGIDAR		np1_nn1
,	,	y
which	which	ddq
resulted	result	vvd
in	in	ii
one	one	mc1
of	of	io
the	the	at
first	first	md
extensive	extensive	jj
comparisons	comparison	nn2
of	of	io
animal	animal	nn1
and	and	cc
human	human	jj
data	data	nn
on	on	ii
abuse	abuse	nn1
potential	potential	nn1
(	(	y
Johanson	johanson	np1
&;		null
Balster	balster	np1
,	,	y
1978	1978	mc
)	)	y
.	.	y
These	these	dd2
were	be	vbdr
heady	heady	jj
times	time	nnt2
for	for	if
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
as	as	csa_ii@
learning	learn	vvg_nn1
theories	theory	nn2
of	of	io
addiction	addiction	nn1
were	be	vbdr
forming	form	vvg
and	and	cc
expanding	expanding	jj_vvg
.	.	y
<p>	<p>	y
After	after	cs_ii
a	a	at1
one-year	one-year	jj
faculty	faculty	nn1
position	position	nn1
at	at	ii
Duke	duke	nn1
,	,	y
Louis	louis	np1
Harris	harris	np1
recruited	recruit	vvd@
me	me	ppio1
to	to	to
join	join	vvi
his	his	appge
Department	department	nn1
of	of	io
Pharmacology	pharmacology	np1_nn1
and	and	cc
Toxicology	toxicology	nn1_np1
at	at	ii
the	the	at
Medical	medical	jj
College	college	nn1
of	of	io
Virginia	virginia	np1
(	(	y
MCV	mcv	mc
)	)	y
,	,	y
where	where	cs_rrq
I	i	ppis1
have	have	vh0
stayed	stay	vvn
ever	ever	rr
since	since	rr@
.	.	y
At	at	ii
this	this	dd1
point	point	nn1
,	,	y
my	my	appge
work	work	nn1
took	take	vvd
a	a	at1
decidedly	decidedly	rr
more	more	rgr
pharmacological	pharmacological	jj
direction	direction	nn1
,	,	y
but	but	ccb
I	i	ppis1
continued	continue	vvd
to	to	to
use	use	vvi
the	the	at
approaches	approach	nn2
and	and	cc
methods	method	nn2
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
throughout	throughout	ii
my	my	appge
career	career	nn1
.	.	y
MCV	mcv	mc
has	have	vhz
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
in	in	ii
the	the	at
pharmacology	pharmacology	nn1
of	of	io
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
and	and	cc
has	have	vhz
a	a	at1
strong	strong	jj
core	core	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacologists	pharmacologist	nn2
,	,	y
some	some	dd
of	of	io
whom	whom	pnqo
were	be	vbdr
my	my	appge
trainees	trainee	nn2
.	.	y
My	my	appge
primary	primary	jj_nn1
areas	area	nn2
of	of	io
research	research	nn1
have	have	vh0
been	be	vbn
with	with	iw
phencyclidine-like		jj
drugs	drug	nn2
,	,	y
abused	abused	jj@_vvn_vvd@
inhalants	inhalant	nn2
,	,	y
and	and	cc
abuse	abuse	vv0@_nn1
potential	potential	jj_nn1
assessment	assessment	nn1
,	,	y
but	but	ccb
including	including	ii
cannabinoids	cannabinoids	nn2
,	,	y
stimulants	stimulant	nn2
,	,	y
and	and	cc
opioids	opioid	nn2
as	as	rr21_rg
well	well	rr22_rr
.	.	y
I	i	ppis1
was	be	vbdz
also	also	rr
fortunate	fortunate	jj
to	to	to@
work	work	vvi
with	with	iw
a	a	at1
strong	strong	jj
group	group	nn1
of	of	io
graduate	graduate	nn1
students	student	nn2
and	and	cc
post-doctoral	postdoctoral	jj
fellows	fellow	nn2
supported	support	vvn
by	by	ii
a	a	at1
National	national	jj
Institute	institute	nn1
on	on	ii
Drug	drug	nn1
Abuse	abuse	nn1
(	(	y
NIDA	nida	np1
)	)	y
training	training	nn1_vvg@
grant	grant	nn1
and	and	cc
individual	individual	jj
fellowships	fellowship	nn2
.	.	y
I	i	ppis1
have	have	vh0
also	also	rr
been	be	vbn
fortunate	fortunate	jj
to	to	to
be	be	vbi
involved	involved	jj
in	in	ii
international	international	jj
collaborations	collaboration	nn2
and	and	cc
training	training	nn1_vvg@
experiences	experience	nn2
.	.	y
<p>	<p>	y
SHARON	sharon	np1
WALSH	walsh	np1
<p>	<p>	y
I	i	ppis1
began	begin	vvd
my	my	appge
graduate	graduate	nn1
training	training	nn1_vvg@
in	in	ii
the	the	at
newly	newly	rr
emerging	emerging	jj_vvg
field	field	nn1
of	of	io
behavioral	behavioral	jj_nn1
neuroscience	neuroscience	nn1
in	in	ii
1985	1985	mc
at	at	ii
Rutgers	rutgers	np1
University	university	nn1
in	in	ii
New	new	np1
Jersey	jersey	np1
.	.	y
My	my	appge
academic	academic	jj
home	home	nn1
was	be	vbdz
in	in	ii
the	the	at
Department	department	nn1
of	of	io
Psychology	psychology	nn1
,	,	y
a	a	at1
department	department	nn1
with	with	iw
a	a	at1
reputation	reputation	nn1
for	for	if
its	its	z'
strength	strength	nn1
in	in	ii
the	the	at
study	study	nn1
and	and	cc
application	application	nn1
of	of	io
classical	classical	jj
and	and	cc
operant	operant	jj_nn1
learning	learning	nn1
theory	theory	nn1
.	.	y
Notable	notable	jj
faculty	faculty	nn1
included	include	vvd
John	john	np1
Falk	falk	np1
,	,	y
Michael	michael	np1
D'Amato	d'amato	np1
,	,	y
Charlie	charlie	np1
Flaherty	flaherty	np1
,	,	y
and	and	cc
George	george	np1
Collier	collier	np1
.	.	y
However	however	rr
,	,	y
as	as	csa_ii
a	a	at1
young	young	jj
student	student	nn1
with	with	iw
interests	interest	nn2
in	in	ii
neuroscience	neuroscience	nn1
and	and	cc
neuropharmacology	neuropharmacology	nn1
,	,	y
my	my	appge
training	training	nn1
extended	extend	vvn_vvd
into	into	ii
affiliated	affiliated	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
and	and	cc
the	the	at
Robert	robert	np1
Wood	wood	np1
Johnson	johnson	np1
Medical	medical	jj
School	school	nn1
.	.	y
My	my	appge
primary	primary	jj_nn1
mentor	mentor	nn1
,	,	y
George	george	np1
Wagner	wagner	np1
,	,	y
trained	train	vvn
with	with	iw
Lew	lew	np1
Selden	selden	np1
,	,	y
the	the	at
notable	notable	jj
behavioral	behavioral	jj_nn1
neuropharmacologist	neuropharmacologist	nn1
at	at	ii
the	the	at
University	university	nn1
of	of	io
Chicago	chicago	np1
.	.	y
Our	our	appge
laboratory	laboratory	nn1
focused	focus	vvd_vvn
primarily	primarily	rr
on	on	ii
the	the	at
evaluation	evaluation	nn1
of	of	io
neurotoxic	neurotoxic	jj
agents	agent	nn2
on	on	ii
behavior	behavior	nn1
and	and	cc
neurochemical	neurochemical	jj
outcomes	outcome	nn2
,	,	y
a	a	at1
new	new	jj
discipline	discipline	nn1
merging	merge	vvg
the	the	at
principles	principle	nn2
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
and	and	cc
neuropharmacology	neuropharmacology	nn1
into	into	ii
behavioral	behavioral	jj_nn1
toxicology	toxicology	nn1
.	.	y
<p>	<p>	y
I	i	ppis1
was	be	vbdz
fortunate	fortunate	jj
to	to	to
complete	complete	vvi
fellowship	fellowship	nn1
training	training	nn1_vvg@
at	at	ii
perhaps	perhaps	rr
the	the	at
most	most	rgt
successful	successful	jj
training	training	nn1
program	program	nn1
in	in	ii
human	human	jj_nn1
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
,	,	y
the	the	at
Behavioral	behavioral	jj_np1_nn1
Pharmacology	pharmacology	nn1_np1
Research	research	nn1
Unit	unit	nn1
at	at	ii
Johns	john	np1
Hopkins	hopkins	np1
University	university	nn1
.	.	y
My	my	appge
mentors	mentor	nn2
included	include	vvd_vvn
Kenzie	kenzie	np1
Preston	preston	np1
,	,	y
George	george	np1
Bigelow	bigelow	np1
,	,	y
and	and	cc
Maxine	maxine	np1
Stitzer	stitzer	np1
.	.	y
I	i	ppis1
arrived	arrive	vvd
at	at	ii
an	a	at1
exciting	exciting	jj
time	time	nnt1
of	of	io
expansion	expansion	nn1
and	and	cc
immediately	immediately	rr
began	begin	vvd
working	work	vvg
on	on	ii_rp@
basic	basic	jj
human	human	jj_nn1
laboratory	laboratory	nn1
studies	study	nn2
of	of	io
an	a	at1
emerging	emerging	jj
medication	medication	nn1
for	for	if
opioid	opioid	jj_nn1
dependence	dependence	nn1
,	,	y
buprenorphine	buprenorphine	vv0_nn1
.	.	y
After	after	ii
completing	complete	vvg
a	a	at1
two-year	two-year	jj
fellowship	fellowship	nn1
,	,	y
I	i	ppis1
was	be	vbdz
offered	offer	vvn
a	a	at1
faculty	faculty	nn1
position	position	nn1
as	as	ii_csa
an	a	at1
Assistant	assistant	jj_nn1
Professor	professor	nn1
and	and	cc
remained	remain	vvd_vvn
at	at	ii
Johns	john	np1
Hopkins	hopkins	np1
for	for	if
another	another	dd1
13	13	mc
years	year	nnt2
.	.	y
Throughout	throughout	ii
that	that	dd1
time	time	nnt1
,	,	y
my	my	appge
work	work	nn1
expanded	expand	vvd_vvn
to	to	to
incorporate	incorporate	vvi
the	the	at
development	development	nn1
of	of	io
medications	medication	nn2
in	in	ii
cocaine	cocaine	nn1
and	and	cc
opioid	opioid	jj_nn1
dependence	dependence	nn1
,	,	y
development	development	nn1
of	of	io
self-administration	self-administration	jj_nn1
procedures	procedure	nn2
incorporating	incorporate	vvg
alternative	alternative	jj_nn1
reinforcers	reinforcer	nn2
,	,	y
and	and	cc
pharmacodynamic	pharmacodynamic	jj
and	and	cc
pharmacokinetic	pharmacokinetic	jj
studies	study	nn2
of	of	io
drugs	drug	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
first	first	md
presentation	presentation	nn1
of	of	io
human	human	jj_nn1
research	research	nn1
to	to	ii
the	the	at
CPDD	cpdd	np1
in	in	ii
1991	1991	mc
and	and	cc
found	find	vvd_vvn
a	a	at1
scientific	scientific	jj
home	home	nn1
among	among	ii
peers	peer	nn2
and	and	cc
supportive	supportive	jj
(	(	y
and	and	cc
sometimes	sometimes	rt
challenging	challenge	vvg_jj
)	)	y
senior	senior	jj
investigators	investigator	nn2
,	,	y
including	including	ii
Marian	marian	np1
Fischman	fischman	np1
,	,	y
Mary	mary	np1
Jeanne	jeanne	np1
Kreek		np1
,	,	y
and	and	cc
Jim	jim	np1
Woods	woods	np1
.	.	y
1	1	mc1
left	left	jj_vvd
Johns	john	np1
Hopkins	hopkins	np1
in	in	ii
2005	2005	mc
for	for	if
a	a	at1
new	new	jj
opportunity	opportunity	nn1
at	at	ii
the	the	at
University	university	nn1
of	of	io
Kentucky	kentucky	np1
in	in	ii
Lexington	lexington	np1
,	,	y
an	a	at1
environment	environment	nn1
steeped	steep	vvn
in	in	ii
the	the	at
history	history	nn1
of	of	io
substance	substance	nn1
abuse	abuse	nn1
research	research	nn1
owing	owing	ii21
to	to	ii22
the	the	at
pioneering	pioneering	jj
work	work	nn1
conducted	conduct	vvn_vvd
at	at	ii
the	the	at
Lexington	lexington	np1_nn1@
Narcotics	narcotic	nn2
Prison	prison	nn1
Farm	farm	nn1
.	.	y
I	i	ppis1
have	have	vh0
been	be	vbn
very	very	rg
fortunate	fortunate	jj
to	to	to@
work	work	vvi
closely	closely	rr
with	with	iw
so	so	rg
many	many	da2
creative	creative	jj
and	and	cc
thoughtful	thoughtful	jj
behavior	behavior	nn1
pharmacologists	pharmacologist	nn2
and	and	cc
to	to	to
find	find	vvi
a	a	at1
small	small	jj
niche	niche	nn1
that	that	cst
allowed	allow	vvd
me	me	ppio1
to	to	to
integrate	integrate	vvi
my	my	appge
early	early	jj
neuropharmacology	neuropharmacology	nn1
training	training	nn1_vvg@
into	into	ii
human	human	jj_nn1
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
.	.	y
<p>	<p>	y
GEORGE	george	np1
BIGELOW	bigelow	np1_nn1
<p>	<p>	y
I	i	ppis1
was	be	vbdz
introduced	introduce	vvn
to	to	ii
the	the	at
operant	operant	jj_nn1
behavioral	behavioral	jj_nn1
perspective	perspective	nn1
in	in	ii
the	the	at
1960s	1960s	mc2
as	as	ii_csa
a	a	at1
psychology	psychology	nn1
undergraduate	undergraduate	nn1
at	at	ii
the	the	at
University	university	nn1
of	of	io
Maryland	maryland	np1
where	where	cs_rrq
several	several	da2
prominent	prominent	jj
operant	operant	jj_nn1
conditioners	conditioner	nn2
were	be	vbdr
on	on	ii
the	the	at
faculty--such	faculty--such	da
as	as	csa
Joseph	joseph	np1
V.	xx_v	ii
Brady	brady	np1
,	,	y
Lewis	lewis	np1
Gollub	gollub	np1
,	,	y
and	and	cc
Jack	jack	np1
Findley--and		np1
I	i	ppis1
received	receive	vvd
practical	practical	jj
primate	primate	nn1
behavioral	behavioral	nn1_jj
laboratory	laboratory	nn1
experience	experience	nn1_vv0
as	as	ii_csa
a	a	at1
research	research	nn1
assistant	assistant	nn1
to	to	ii
Charles	charles	np1
Ferster	ferster	np1_nn1
at	at	ii
the	the	at
Institute	institute	nn1
for	for	if
Behavioral	behavioral	jj_nn1_np1
Research	research	nn1
.	.	y
This	this	dd1
background	background	nn1
and	and	cc
experience	experience	nn1
were	be	vbdr
instrumental	instrumental	jj
in	in	ii
helping	help	vvg
me	me	ppio1
arrange	arrange	vvi
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
to	to	to
graduate	graduate	vvi
school	school	nn1
at	at	ii
the	the	at
University	university	nn1
of	of	io
Minnesota	minnesota	np1
,	,	y
where	where	cs_rrq
Thompson	thompson	np1
directed	direct	vvd
the	the	at
training	training	nn1
program	program	nn1
in	in	ii
psychopharmacology	psychopharmacology	nn1
.	.	y
Thompson	thompson	np1
and	and	cc
C.R.	cr	np1
Schuster	schuster	np1
had	have	vhd
just	just	rr
recently	recently	rr
done	do	vdn
the	the	at
first	first	md
studies	study	nn2
of	of	io
opioid	opioid	jj_nn1
drug	drug	nn1
self-administration	self-administration	nn1
in	in	ii
primates	primate	nn2
and	and	cc
were	be	vbdr
working	work	vvg
on	on	ii_rp@
their	their	appge
classic	classic	jj_nn1
textbook	textbook	nn1
,	,	y
Behavioral		np1_jj
Pharmacology	pharmacology	np1_nn1
.	.	y
It	it	pph1
was	be	vbdz
a	a	at1
wonderful	wonderful	jj
training	training	nn1
environment	environment	nn1
,	,	y
with	with	iw
excellent	excellent	jj
opportunities	opportunity	nn2
and	and	cc
faculty	faculty	nn1
and	and	cc
an	a	at1
outstanding	outstanding	jj
group	group	nn1
of	of	io
graduate	graduate	nn1
students	student	nn2
,	,	y
many	many	da2
of	of	io
whom	whom	pnqo
have	have	vh0
gone	go	vvn
on	on	rp
to	to	to
make	make	vvi
substantial	substantial	jj
contributions	contribution	nn2
in	in	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
.	.	y
It	it	pph1
was	be	vbdz
here	here	rl
!	!	y
began	begin	vvd
studying	study	vvg
drug-behavior	drug-behavior	jj_nn1
interactions	interaction	nn2
,	,	y
and	and	cc
I	i	ppis1
stayed	stay	vvd
on	on	rp@
for	for	if
postdoctoral	postdoctoral	jj_nn1
training	training	nn1
in	in	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
,	,	y
working	work	vvg
with	with	iw
Roy	roy	np1
Pickens	pickens	np1
,	,	y
beginning	begin	vvg
a	a	at1
decades-long	decades-long	jj
collaboration	collaboration	nn1
with	with	iw
Roland	roland	np1
Griffiths	griffiths	np1
,	,	y
and	and	cc
beginning	begin	vvg_nn1
to	to	to
extend	extend	vvi
my	my	appge
work	work	nn1
and	and	cc
interests	interest	nn2
to	to	ii
human	human	jj_nn1
research	research	nn1
.	.	y
Subsequently	subsequently	rr
,	,	y
I	i	ppis1
have	have	vh0
only	only	rr
had	have	vhn
one	one	mc1
job	job	nn1
:	:	y
I	i	ppis1
was	be	vbdz
recruited	recruit	vvn
by	by	ii
Joe	joe	np1
Brady	brady	np1
and	and	cc
Lou	lou	np1
Faillace		np1
in	in	ii
1971	1971	mc
to	to	ii
my	my	appge
current	current	jj
position	position	nn1
at	at	ii
Johns	john	np1
Hopkins	hopkins	np1
,	,	y
focusing	focus	vvg
primarily	primarily	rr
on	on	ii
human	human	jj_nn1
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
related	relate	vvn_vvd
to	to	ii
substance	substance	nn1
abuse	abuse	nn1
.	.	y
<p>	<p>	y
At	at	ii
Hopkins	hopkins	np1
,	,	y
we	we	ppis2
developed	develop	vvd
a	a	at1
postdoctoral	postdoctoral	jj_nn1
research	research	nn1
training	training	nn1
program	program	nn1
on	on	ii
the	the	at
human	human	jj_nn1
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
of	of	io
substance	substance	nn1
that	that	cst_dd1
has	have	vhz
now	now	rt
been	be	vbn
supported	support	vvn
by	by	ii
the	the	at
National	national	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
over	over	rg
25	25	mc
years	year	nnt2
.	.	y
From	from	ii
the	the	at
beginning	beginning	nn1
,	,	y
our	our	appge
core	core	nn1
faculty	faculty	nn1
were	be	vbdr
Roland	roland	np1
Griffiths	griffiths	np1
,	,	y
Maxine	maxine	np1
Stitizer		np1
,	,	y
Ira	ira	np1
Liebson		np1
,	,	y
and	and	cc
me	me	ppio1
.	.	y
Our	our	appge
goal	goal	nn1
has	have	vhz
been	be	vbn
to	to	to
apply	apply	vvi
rigorous	rigorous	jj
,	,	y
parametric	parametric	jj
,	,	y
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
methods	method	nn2
to	to	ii
human	human	jj_nn1
research	research	nn1
on	on	ii
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
,	,	y
both	both	rr_db2
in	in	ii
the	the	at
laboratory	laboratory	nn1
and	and	cc
the	the	at
clinic	clinic	nn1
,	,	y
to	to	to
extend	extend	vvi
these	these	dd2
methods	method	nn2
to	to	ii_to
all	all	rr@
(	(	y
or	or	cc
most	most	dat_rgt
)	)	y
major	major	jj
classes	class	nn2
of	of	io
abused	abused	jj@
drugs	drug	nn2
,	,	y
and	and	cc
to	to	to
develop	develop	vvi
a	a	at1
program	program	nn1
of	of	io
research	research	nn1
extending	extend	vvg
from	from	ii
human	human	jj_nn1
laboratory	laboratory	nn1
basic	basic	jj
science	science	nn1
to	to	ii
outpatient	outpatient	nn1
applied	applied	jj_vvd_vvn
therapeutics	therapeutics	nn1
.	.	y
Major	major	jj_np1
themes	theme	nn2
or	or	cc
methodologies	methodology	nn2
have	have	vh0
included	include	vvn
drug	drug	nn1
self-administration	self-administration	nn1
,	,	y
drug	drug	nn1
discrimination	discrimination	nn1
,	,	y
abuse	abuse	nn1_vv0@
liability	liability	nn1
assessment	assessment	nn1
,	,	y
evaluation	evaluation	nn1
of	of	io
performance	performance	nn1
effects	effect	nn2
,	,	y
medications	medication	nn2
development	development	nn1
for	for	if
substance	substance	nn1
abuse	abuse	nn1
treatment	treatment	nn1
,	,	y
contingency	contingency	nn1
management	management	nn1
treatment	treatment	nn1
,	,	y
and	and	cc
**26;5716;TOOLONG		jj
integration	integration	nn1
.	.	y
The	the	at
NIDA	nida	nn1_np1
training	training	nn1
grant	grant	nn1
has	have	vhz
provided	provide	vvn
a	a	at1
vehicle	vehicle	nn1
for	for	if
working	work	vvg
with	with	iw
and	and	cc
collaborating	collaborate	vvg
with	with	iw
a	a	at1
wonderful	wonderful	jj
array	array	nn1
of	of	io
young	young	jj
scientists	scientist	nn2
who	who	pnqs
have	have	vh0
continued	continue	vvn
to	to	to
expand	expand	vvi
the	the	at
frontiers	frontier	nn2
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
research	research	nn1
and	and	cc
its	its	z'
application	application	nn1
to	to	ii
problems	problem	nn2
of	of	io
drug	drug	nn1
abuse	abuse	nn1
,	,	y
dependence	dependence	nn1
,	,	y
and	and	cc
treatment	treatment	nn1
.	.	y
Some	some	dd
of	of	io
these	these	dd2
training	training	nn1_vvg@
program	program	nn1
graduates	graduate	nn2
have	have	vh0
stayed	stay	vvn
on	on	rp@_ii
and	and	cc
contributed	contribute	vvn_vvd
to	to	ii
our	our	appge
faculty	faculty	nn1
enrichment	enrichment	nn1
at	at	ii
Hopkins	hopkins	np1
,	,	y
whereas	whereas	cs
others	others	nn2
have	have	vh0
developed	develop	vvn
similar	similar	jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
me	me	ppio1
that	that	dd1_cst
training	training	nn1
programs	program	nn2
developed	develop	vvn
by	by	ii
graduates	graduate	nn2
of	of	io
our	our	appge
program	program	nn1
are	be	vbr
now	now	rt
sending	send	vvg
us	us	ppio2
their	their	appge
graduates	graduate	nn2
to	to	to
be	be	vbi
new	new	jj
members	member	nn2
of	of	io
our	our	appge
faculty	faculty	nn1
team	team	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
ACKNOWLEDGEMENTS	acknowledgement	nn2
This	this	dd1
paper	paper	nn1
is	be	vbz
based	base	vvn
on	on	ii
presentations	presentation	nn2
at	at	ii
a	a	at1
May	may	npm1
2006	2006	mc
conference	conference	nn1
in	in	ii
Key	key	np1
Largo	largo	np1
,	,	y
Florida	florida	np1
entitled	entitle	vvn_vvd%
Reflections	reflection	nn2
on	on	ii
40	40	mc
Years	year	nnt2
of	of	io
Drug	drug	nn1
Abuse	abuse	nn1
Research	research	nn1
.	.	y
The	the	at
authors	author	nn2
acknowledge	acknowledge	vv0
,	,	y
with	with	iw
thanks	thanks	nn2
,	,	y
the	the	at
contribution	contribution	nn1
of	of	io
James	james	np1
Woods	woods	np1
to	to	ii
the	the	at
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
presentations	presentation	nn2
at	at	ii
the	the	at
conference	conference	nn1
.	.	y
NIDA	nida	np1_nn1
grants	grant	vvz
DA-01442	da-01442	mc
(	(	y
Balster	balster	np1
)	)	y
,	,	y
DA016718		fo
DA019433		fo
and	and	cc
DA022191		fo
(	(	y
Walsh	walsh	np1
)	)	y
,	,	y
and	and	cc
DA08045		fo
,	,	y
DA013034		fo
and	and	cc
DA019497		fo
(	(	y
Bigelow	bigelow	np1
)	)	y
supported	support	vvd_jj@
preparation	preparation	nn1
of	of	io
this	this	dd1
manuscript	manuscript	nn1
.	.	y
<p>	<p>	y
L	l	zz1_np1@
:	:	y
REFERENCES	reference	nn2_vvz@
--		zz
American	american	jj
Psychiatric	psychiatric	jj
Association	association	nn1
.	.	y
2000	2000	mc
Diagnostic	diagnostic	jj
and	and	cc
statistical	statistical	jj
manual	manual	nn1
of	of	io
mental	mental	jj
disorders	disorder	nn2
.	.	y
(	(	y
4th	4th	md
ed	ed	nn1
.	.	y
)	)	y
,	,	y
(	(	y
DSM	dsm	np1
IV	iv	mc
)	)	y
.	.	y
Washington	washington	np1
,	,	y
DC	dc	np1
:	:	y
American	american	jj
Psychiatric	psychiatric	jj
Association	association	nn1
.	.	y
<p>	<p>	y
--		zz
Anderson	anderson	np1
,	,	y
R.L.	rl	np1
,	,	y
Velkey		np1
,	,	y
A.J.	aj	np1
,	,	y
&;		null
Woolverton	woolverton	np1
,	,	y
W.R.	wr	np1
2002	2002	mc
The	the	at
generalized	generalized	jj
matching	matching	jj_nn1
law	law	nn1
as	as	ii_csa
a	a	at1
predictor	predictor	nn1
of	of	io
choice	choice	nn1
between	between	ii
cocaine	cocaine	nn1
and	and	cc
food	food	nn1
in	in	ii
rhesus	rhesus	nn1
monkeys	monkey	nn2
.	.	y
Psychopharmacology	psychopharmacology	nn1_np1@
,	,	y
163	163	mc
,	,	y
319-326		mcmc
.	.	y
<p>	<p>	y
--		zz
Balster	balster	nn1_np1
,	,	y
R.L.	rl	np1
1991	1991	mc
Drug	drug	nn1
abuse	abuse	nn1
potential	potential	nn1_jj
evaluation	evaluation	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
1549-1558		mcmc
.	.	y
<p>	<p>	y
--		zz
Balster	balster	nn1_np1
,	,	y
R.L.	rl	np1
,	,	y
&;		null
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E	ge	np1
.	.	y
2003	2003	mc
Guidelines	guideline	nn2
and	and	cc
methodological	methodological	jj
reviews	review	nn2
concerning	concerning	ii_vvg
drug	drug	nn1
abuse	abuse	nn1
liability	liability	nn1
assessment	assessment	nn1
.	.	y
Drug	drug	nn1
and	and	cc
Alcohol	alcohol	nn1
Dependence	dependence	nn1
,	,	y
70	70	mc
(	(	y
Suppl.	suppl	np1
3	3	mc
)	)	y
,	,	y
S13-S40		nn1_jj
.	.	y
<p>	<p>	y
--		zz
Barrett	barrett	np1
,	,	y
J.E	je	np1
.	.	y
2002	2002	mc
The	the	at
emergence	emergence	nn1
of	of	io
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
.	.	y
Molecular	molecular	jj
interventions	intervention	nn2
,	,	y
2	2	mc
,	,	y
470-475		mcmc
.	.	y
<p>	<p>	y
--		zz
Belknap	belknap	nn1_np1
,	,	y
J.K.	jk	np1
,	,	y
Metten		np1_vv0
,	,	y
P.	xx_p	np1
,	,	y
Beckley	beckley	np1
,	,	y
E.H.	e.h	np1
,	,	y
&;		null
Crabbe	crabbe	np1
,	,	y
J.C	jc	np1
.	.	y
2008	2008	mc
Multivariate	multivariate	jj
analyses	analysis	nn2
reveal	reveal	vv0
common	common	jj
and	and	cc
drug-specific	drug-specific	jj
genetic	genetic	jj
influences	influence	nn2
on	on	ii
responses	response	nn2
to	to	ii
four	four	mc
drugs	drug	nn2
of	of	io
abuse	abuse	nn1
.	.	y
Trends	trend	nn2
in	in	ii
Pharmacological	pharmacological	jj_np1
Sciences	science	nn2
,	,	y
29	29	mc
,	,	y
547-543		mcmc
.	.	y
<p>	<p>	y
--		zz
Bickel	bickel	np1_nn1@
,	,	y
W.K.	wk	np1
,	,	y
&;		null
Marsch	marsch	np1_nn1
,	,	y
L.A.	la	np1
2001	2001	mc
Toward	toward	ii
a	a	at1
behavioral	behavioral	jj
economic	economic	jj
understanding	understanding	nn1
of	of	io
drug	drug	nn1
dependence	dependence	nn1
:	:	y
Delay	delay	vv0_nn1
discounting	discount	vvg_nn1
processes	process	nn2
.	.	y
Addiction	addiction	npx
,	,	y
96	96	mc
,	,	y
73-86	73-86	mcmc
.	.	y
<p>	<p>	y
--		zz
Bickel	bickel	np1_nn1@
,	,	y
W.K.	wk	np1
,	,	y
Marsch	marsch	np1_nn1
,	,	y
L.A.	la	np1
,	,	y
&;		null
Carroll	carroll	np1
,	,	y
M.E.	me	nn1
2000	2000	mc
Deconstructing	deconstruct	jj@_np1_vvg
relative	relative	nn1_jj
reinforcing	reinforce	vvg_jj@
efficacy	efficacy	nn1
and	and	cc
situating	situate	vvg
the	the	at
measures	measure	nn2
of	of	io
pharmacological	pharmacological	jj
reinforcement	reinforcement	nn1
with	with	iw
behavioral	behavioral	jj
economics	economics	nn1
:	:	y
A	a	zz1_at1@
theoretical	theoretical	jj
proposal	proposal	nn1
.	.	y
Psychophamacology	psychophamacology	nn1_np1@
,	,	y
153	153	mc
,	,	y
44-56	44-56	mcmc
.	.	y
<p>	<p>	y
--		zz
Brady	brady	np1
,	,	y
J.V.	jv	np1
,	,	y
&;		null
Griffiths	griffiths	np1
,	,	y
R.R.	xx_rr	np1
1976	1976	mc
Behavioral	behavioral	jj
procedures	procedure	nn2
for	for	if
evaluating	evaluate	vvg
the	the	at
relative	relative	jj_nn1
abuse	abuse	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
35	35	mc
,	,	y
2245-2253		mcmc
.	.	y
<p>	<p>	y
--		zz
Carroll	carroll	np1
,	,	y
K.M.	k.m	nnu
,	,	y
&;		null
Onken	onken	np1_nn1
,	,	y
L.S.	l.s	nnu2
2005	2005	mc
Behavioral	behavioral	jj
therapies	therapy	nn2
for	for	if
drug	drug	nn1
abuse	abuse	nn1
.	.	y
American	american	jj
Journal	journal	nn1
of	of	io
Psychiatry	psychiatry	np1_nn1
,	,	y
162	162	mc
,	,	y
1452-1460		mcmc
.	.	y
<p>	<p>	y
--		zz
Chait	chait	nn1_np1
,	,	y
L.D.	ld	np1
,	,	y
Uhlenhuth	uhlenhuth	np1_nn1
,	,	y
E.H.	e.h	np1
,	,	y
&;		null
Johanson	johanson	np1
,	,	y
C.E.	ce	np1
1984	1984	mc
An	a	at1
experimental	experimental	jj
paradigm	paradigm	nn1
for	for	if
studying	study	vvg
the	the	at
discriminative	discriminative	jj
stimulus	stimulus	nn1
properties	property	nn2
of	of	io
drugs	drug	nn2
in	in	ii
humans	human	nn2
.	.	y
Psychopharmacology	psychopharmacology	nn1_np1@
,	,	y
82	82	mc
,	,	y
272-274		mcmc
.	.	y
<p>	<p>	y
--		zz
Collins	collins	np1
,	,	y
L.M.	lm	np1
,	,	y
&;		null
Sayer	sayer	np1_nn1
,	,	y
A.G.	a.g	fo
(	(	y
Eds.	eds	nn2
)	)	y
2001	2001	mc
New	new	jj
methods	method	nn2
for	for	if
the	the	at
analysis	analysis	nn1
of	of	io
change	change	nn1
.	.	y
Washington	washington	np1
,	,	y
DC	dc	np1
:	:	y
American	american	jj
Psychological	psychological	jj
Association	association	nn1
.	.	y
<p>	<p>	y
--		zz
Dole	dole	np1_nn1@
,	,	y
V.P.	vp	np1
,	,	y
&;		null
Nyswander		np1_vv0_nn1
,	,	y
M.	m	nn1
1965	1965	mc
A	a	zz1_at1@
medical	medical	jj
treatment	treatment	nn1
for	for	if
diacetylmorphine	diacetylmorphine	nn1
(	(	y
heroin	heroin	nn1
)	)	y
addiction	addiction	nn1
,	,	y
a	a	at1
clinical	clinical	jj
trial	trial	nn1
with	with	iw
methadone	methadone	nn1
hydrochloride	hydrochloride	nn1
.	.	y
Journal	journal	nn1
of	of	io
the	the	at
American	american	jj
Medical	medical	jj
Association	association	nn1
,	,	y
193	193	mc
,	,	y
646-650		mcmc
.	.	y
<p>	<p>	y
--		zz
Deneau	deneau	nn1_np1
,	,	y
G.A.	g.a	np1
,	,	y
Yanagita	yanagita	np1
,	,	y
T.	t	np1
,	,	y
&;		null
Seevers	seevers	np1_vvz
,	,	y
M.H.	mh	np1
1969	1969	mc
Self-administration	self-administration	nn1_jj
of	of	io
psychoactive	psychoactive	jj
substances	substance	nn2
by	by	ii
the	the	at
monkey--A	monkey--a	nn1
measure	measure	nn1
of	of	io
psychological	psychological	jj
dependence	dependence	nn1
.	.	y
Psychopharmacologia	psychopharmacologia	nn1_np1@
,	,	y
16	16	mc
,	,	y
30-48	30-48	mcmc
.	.	y
<p>	<p>	y
--		zz
Fischman	fischman	nn1_np1
,	,	y
M.W.	m.w	nnu
,	,	y
&;		null
Mello	mello	np1
,	,	y
N.K.	nk	np1
(	(	y
Eds.	eds	nn2
)	)	y
.	.	y
1989	1989	mc
Testing	testing	nn1_vvg_np1
for	for	if
abuse	abuse	nn1
liability	liability	nn1
of	of	io
drugs	drug	nn2
in	in	ii
humans	human	nn2
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
DHHS	dhhs	np1
,	,	y
Pub	pub	nn1
.	.	y
No	no	xx
.	.	y
(	(	y
ADM	adm	np1
)	)	y
89-I	89-i	mc
613	613	mc
.	.	y
Rockville	rockville	np1
,	,	y
MD	md	nna
:	:	y
Alcohol	alcohol	nn1
,	,	y
Drug	drug	nn1
Abuse	abuse	nn1
,	,	y
and	and	cc
Mental	mental	jj
Health	health	nn1
Administration	administration	nn1
.	.	y
<p>	<p>	y
--		zz
Fischman	fischman	nn1_np1
,	,	y
M.W.	m.w	nnu
,	,	y
&;		null
Schuster	schuster	np1_nn1
,	,	y
C.R.	cr	np1
1982	1982	mc
Cocaine	cocaine	nn1
self-administration	self-administration	nn1
in	in	ii
humans	human	nn2
.	.	y
Federation	federation	nn1
Proceedings	proceedings	nn2
,	,	y
41	41	mc
,	,	y
241-246		mcmc
.	.	y
<p>	<p>	y
--		zz
Griffiths	griffiths	np1
,	,	y
R.R.	xx_rr	np1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E.	g.e	np1
,	,	y
&;		null
Henningfield	henningfield	np1
,	,	y
J.E	je	np1
.	.	y
1980	1980	mc
Similarities	similarity	nn2
in	in	ii
animal	animal	nn1
and	and	cc
human	human	jj_nn1
drug-taking	drug-taking	nn1
behavior	behavior	nn1
.	.	y
In	in	ii
N.K.	nk	np1
Mello	mello	np1
(	(	y
Ed	ed	np1
.	.	y
)	)	y
,	,	y
Advances	advance	nn2_vvz
in	in	ii
substance	substance	nn1
abuse	abuse	nn1
:	:	y
Behavioral		np1_jj_nn1
and	and	cc
biological	biological	jj
research	research	nn1
(	(	y
pp.	pp	nnu2
1-90	1-90	mcmc
)	)	y
.	.	y
Greenwich	greenwich	np1
,	,	y
CT	ct	np1@_nn1
:	:	y
JAI	jai	jj_np1_nn2
Press	press	nn1_vv0
,	,	y
Inc	inc	jj
.	.	y
<p>	<p>	y
--		zz
Harris	harris	np1
,	,	y
R.T.	rt	np1
,	,	y
&;		null
Balster	balster	np1_nn1
,	,	y
R.L.	rl	np1
1968	1968	mc
Discriminative	discriminative	jj
control	control	nn1
by	by	ii
d.l-amphetamine	d.l-amphetamine	nn1_jj
and	and	cc
saline	saline	jj
of	of	io
lever	lever	nn1
choice	choice	nn1
and	and	cc
response	response	nn1
patterning	pattern	vvg_nn1@
.	.	y
Psychonomic	psychonomic	jj
Science	science	nn1
,	,	y
10	10	mc
,	,	y
106-107	106-107	mcmc
.	.	y
<p>	<p>	y
--		zz
Henningfield	henningfield	np1_nn1@
,	,	y
J.E.	j.e	np1
,	,	y
&;		null
Fant	fant	np1_nn1
,	,	y
R.V.	rv	np1
1999	1999	mc
Tobacco	tobacco	nn1
use	use	nn1_vv0
as	as	csa_ii@
drug	drug	nn1
addiction	addiction	nn1
:	:	y
The	the	at
experimental	experimental	jj
evidence	evidence	nn1
.	.	y
Nicotine	nicotine	nn1
and	and	cc
Tobacco	tobacco	nn1
Research	research	nn1
,	,	y
1	1	mc1
(	(	y
Suppl.	suppl	np1
1	1	mc1
)	)	y
,	,	y
S31-S35		nn1_jj
.	.	y
<p>	<p>	y
--		zz
Higgins	higgins	np1
,	,	y
S.T.	st	np1
,		np1
Alessi	alessi	np1
,	,	y
S.M.	sm	np1
,	,	y
&;		null
Dantona		np1
,	,	y
R.L.	rl	np1
2002	2002	mc
Voucher-based	voucher-based	jj
incentives	incentive	nn2
.	.	y
A	a	at1
substance	substance	nn1
abuse	abuse	nn1
treatment	treatment	nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
--		zz
Higgins	higgins	np1
,	,	y
S.T.	st	np1
,		np1
Bickel	bickel	np1
,	,	y
W.K.	wk	np1
,	,	y
&;		null
Hughes	hughes	np1
,	,	y
J.R	j.r	nna
.	.	y
1994	1994	mc
Influence	influence	nn1
of	of	io
an	a	at1
alternative	alternative	jj_nn1
reinforcer	reinforcer	nn1
on	on	ii
human	human	jj_nn1
cocaine	cocaine	nn1
self	self	nn1
administration	administration	nn1
.	.	y
Life	life	nn1
Sciences	science	nn2
,	,	y
55	55	mc
,	,	y
179-187		mcmc
.	.	y
<p>	<p>	y
--		zz
Higgins	higgins	np1
,	,	y
S.T.	st	np1
,		np1
Budney	budney	np1
,	,	y
A.J.	aj	np1
,	,	y
Bickel	bickel	np1
,	,	y
W.K.	wk	np1
,	,	y
Hughes	hughes	np1
,	,	y
J.R.	j.r	nna
,	,	y
Foerg		np1_vv0_nn1
,	,	y
F.	f	np1_ra@
,	,	y
&;		null
Badger	badger	nn1_vv0@
,	,	y
G.	g	np1
1993	1993	mc
Achieving	achieve	vvg
cocaine	cocaine	nn1
abstinence	abstinence	nn1
with	with	iw
a	a	at1
behavioral	behavioral	jj_nn1
approach	approach	nn1
.	.	y
American	american	jj
Journal	journal	nn1
of	of	io
Psychiatry	psychiatry	np1_nn1
,	,	y
150	150	mc
,	,	y
763-769		mcmc
.	.	y
<p>	<p>	y
--		zz
Johanson	johanson	np1_nn1@
,	,	y
C.E.	ce	np1
,	,	y
&;		null
Balster	balster	np1_nn1
,	,	y
R.L.	rl	np1
1978	1978	mc
A	a	zz1_at1@
summary	summary	nn1
of	of	io
results	result	nn2
of	of	io
drug	drug	nn1
self-administration	self-administration	nn1_jj
studies	study	nn2
using	use	vvg
substitution	substitution	nn1
procedures	procedure	nn2
in	in	ii
rhesus	rhesus	nn1
monkeys	monkey	nn2
.	.	y
Bulletin	bulletin	nn1
on	on	ii
Narcotics	narcotic	nn2
,	,	y
30	30	mc
,	,	y
43-54	43-54	mcmc
.	.	y
<p>	<p>	y
--		zz
Kenny	kenny	np1
,	,	y
P.J.	pj	np1
2007	2007	mc
Brain	brain	nn1
reward	reward	nn1
systems	system	nn2
and	and	cc
compulsive	compulsive	jj
drug	drug	nn1
use	use	nn1
.	.	y
Trends	trend	nn2
in	in	ii
Pharmacological	pharmacological	jj_np1
Science	science	nn1
,	,	y
28	28	mc
,	,	y
135-14		mcmc
I.	i	np1
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.F.	gf	np1
1992	1992	mc
Neural	neural	jj
mechanisms	mechanism	nn2
of	of	io
drug	drug	nn1
reinforcement	reinforcement	nn1
.	.	y
Annals	annal	nn2
of	of	io
the	the	at
New	new	np1
York	york	np1
Academy	academy	nn1
of	of	io
Sciences	science	nn2
,	,	y
28	28	mc
,	,	y
171	171	mc
-	-	-
19	19	mc
I.	i	np1
<p>	<p>	y
--		zz
Koob	koob	np1_nn1@
,	,	y
G.R.	gr	np1
,	,	y
&;		null
Le	le	np1
Moal	moal	np1
,	,	y
M.	m	nn1
2006	2006	mc
Neurobiology	neurobiology	nn1
of	of	io
Addiction	addiction	npx
.	.	y
London	london	np1
:	:	y
Academic	academic	jj
Press	press	nn1
.	.	y
<p>	<p>	y
--		zz
Kreek		np1_nn1@
,	,	y
M.J.	mj	np1
,	,	y
Nielsen	nielsen	np1
,	,	y
D.A.	da	np1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
:	:	y
Alcoholism	alcoholism	nn1
,	,	y
opiate	opiate	nn1_vv0
and	and	cc
cocaine	cocaine	nn1
addiction	addiction	nn1
.	.	y
Neuromolecular	neuromolecular	jj
Medicine	medicine	nn1
,	,	y
5	5	mc
,	,	y
85-108		mcmc
.	.	y
<p>	<p>	y
--		zz
Madras	madras	np1_nn1@
,	,	y
B.K.	bk	np1
,	,	y
Colvis		np1
,	,	y
C.M.	c.m	nnu
,	,	y
Pollock	pollock	np1
,	,	y
J.D.	jd	np1
,	,	y
Rutter	rutter	np1
,	,	y
J.L.	jl	np1
,	,	y
Shurtleff	shurtleff	np1_vv0_nn1
,	,	y
D.	d	np1
,	,	y
&;		null
von	von	np1
Zastrow		np1
,	,	y
:	:	y
M.	m	nnu@_nn1
(	(	y
Eds.	eds	nn2
)	)	y
2006	2006	mc
Cell	cell	nn1
biology	biology	nn1
of	of	io
addiction	addiction	nn1
.	.	y
Cold	cold	jj_nn1
Spring	spring	nn1
Harbor	harbor	nn1
,	,	y
NY	ny	np1
:	:	y
Cold	cold	jj
Spring	spring	nn1
Harbor	harbor	nn1
Laboratory	laboratory	nn1
Press	press	nn1
.	.	y
<p>	<p>	y
--		zz
Martin	martin	np1
,	,	y
W.R.	wr	np1
,	,	y
Sloan	sloan	np1_nn1
,	,	y
B.S.	bs	np1
,	,	y
Sapira	sapira	np1
,	,	y
J.D.	jd	np1
,	,	y
&;		null
Jasinski	jasinski	np1_nn1
,	,	y
D.R.	d.r	nnb
1971	1971	mc
Physiologic	physiologic	jj
,	,	y
subjective	subjective	jj
,	,	y
and	and	cc
behavioral	behavioral	jj_nn1
effects	effect	nn2
of	of	io
amphetamine	amphetamine	nn1
,	,	y
methamphetamine	methamphetamine	vv0_nn1
,	,	y
ephedrine	ephedrine	nn1_jj
,	,	y
phenmetrazine	phenmetrazine	nn1
,	,	y
and	and	cc
methylphenidaie	methylphenidaie	nn1
in	in	ii
man	man	nn1
.	.	y
Clinical	clinical	jj
Pharmacology	pharmacology	nn1
and	and	cc
Therapeutics	therapeutics	nn1
,	,	y
12	12	mc
,	,	y
245-258		mcmc
.	.	y
<p>	<p>	y
--		zz
McKim	mckim	np1
,	,	y
W.	w	np1
2006	2006	mc
Drugs	drug	nn2
and	and	cc
behavior	behavior	nn1
:	:	y
An	a	at1
introduction	introduction	nn1
to	to	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
,	,	y
(	(	y
6th	6th	md
ed	ed	nn1
.	.	y
)	)	y
.	.	y
Upper	upper	jj
Saddle	saddle	np1
River	river	nnl1
,	,	y
N	xx_n	zz1
J	xx_j	zz1
:	:	y
Pearson	pearson	np1
.	.	y
<p>	<p>	y
--		zz
Mello	mello	np1_nn1@
,	,	y
N.K.	nk	np1
,	,	y
&;		null
Mendelson	mendelson	np1
,	,	y
J.H.	jh	np1
1965	1965	mc
Operant	operant	jj
analysis	analysis	nn1
of	of	io
drinking	drink	vvg_nn1
patterns	pattern	nn2
of	of	io
chronic	chronic	jj
alcoholics	alcoholic	nn2
.	.	y
Nature	nature	nn1
,	,	y
,	,	y
206	206	mc
,	,	y
43	43	mc
-46	-46	mc
.	.	y
<p>	<p>	y
--		zz
Mello	mello	np1_nn1@
,	,	y
N.K.	nk	np1
,	,	y
&;		null
Mendelson	mendelson	np1
,	,	y
J.H.	jh	np1
1978	1978	mc
Heroin	heroin	nn1
self-administration	self-administration	nn1
:	:	y
An	a	at1
operant	operant	jj_nn1
analysis	analysis	nn1
.	.	y
NIDA	nida	np1_nn1
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
R.E.	re	np1
,	,	y
McNamee	mcnamee	np1
,	,	y
H.B.	hb	np1
,	,	y
Mirin	mirin	np1_nn1
,	,	y
S.M.	sm	np1
,	,	y
&;		null
Altman	altman	np1
,	,	y
J.L.	jl	np1
1976	1976	mc
Analysis	analysis	nn1
and	and	cc
modification	modification	nn1
of	of	io
opiate	opiate	nn1
reinforcement	reinforcement	nn1
.	.	y
The	the	at
International	international	jj
Journal	journal	nn1
of	of	io
the	the	at
Addictions	addiction	npx
,	,	y
11	11	mc
,	,	y
467-484		mcmc
.	.	y
<p>	<p>	y
--		zz
Morse	morse	np1_nn1@
,	,	y
W.H.	wh	np1
,	,	y
&;		null
Kelleher	kelleher	np1
,	,	y
R.T	rt	np1
.	.	y
1970	1970	mc
Schedules	schedule	nn2
as	as	csa_rg@
fundamental	fundamental	jj
determinants	determinant	nn2
of	of	io
behavior	behavior	nn1
.	.	y
In	in	ii
W.N.	wn	np1
Schoenfeld	schoenfeld	np1
(	(	y
Ed	ed	np1
.	.	y
)	)	y
,	,	y
The	the	at
Theory	theory	nn1
of	of	io
Reinforcement	reinforcement	nn1
Schedules	schedule	nn2
(	(	y
pp.	pp	nnu2
43-61	43-61	mcmc
)	)	y
.	.	y
New	new	np1
York	york	np1
:	:	y
Appleton-Century-Crofts	appleton-century-crofts	np1
.	.	y
<p>	<p>	y
--		zz
Nelson	nelson	np1
,	,	y
A.	a	zz
,	,	y
&;		null
Killcross		np1_vv0_nn1
,	,	y
S.	s	np1
2006	2006	mc
Amphetamine	amphetamine	np1
exposure	exposure	nn1
enhances	enhance	vvz
habit	habit	nn1
formation	formation	nn1
.	.	y
Journal	journal	nn1
of	of	io
Neuroscience	neuroscience	np1
,	,	y
26	26	mc
,	,	y
3805-3812		mcmc
.	.	y
<p>	<p>	y
--		zz
Petry	petry	nn1_np1
,	,	y
N.M.	n.m	np1
,	,	y
&;		null
Martin	martin	np1
,	,	y
B.	b	np1
2002	2002	mc
Low-cost	low-cost	jj
contingency	contingency	nn1
management	management	nn1
for	for	if
treating	treat	vvg
cocaine-	cocaine-	jj_nn1
and	and	cc
opioid	opioid	jj_nn1
abusing	abuse	jj@_nn1@_vvg
methadone	methadone	nn1
patients	patient	nn2
.	.	y
Journal	journal	nn1
of	of	io
Consulting	consulting	nn1_jj_vvg
and	and	cc
Clinical	clinical	jj
Psychology	psychology	nn1
,	,	y
70	70	mc
,	,	y
398-405		mcmc
.	.	y
<p>	<p>	y
--		zz
Pickens	pickens	nn2_np1
,	,	y
R.W.	rw	np1
1977	1977	mc
Behavioral	behavioral	jj
pharmacology	pharmacology	nn1
:	:	y
A	a	zz1_at1@
brief	brief	jj
history	history	nn1
.	.	y
In	in	ii
T.	t	np1
Thompson	thompson	np1
&;		null
P.B.	p.b	fo
Dews	dew	nn2
(	(	y
Eds	ed	nn2
.	.	y
)	)	y
,	,	y
Advances	advance	nn2_vvz
in	in	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
(	(	y
pp.	pp	nnu2
229-257		mcmc
)	)	y
.	.	y
New	new	np1
York	york	np1
:	:	y
Academic	academic	jj
Press	press	nn1
.	.	y
<p>	<p>	y
--		zz
Pickens	pickens	nn2_np1
,	,	y
R.W.	rw	np1
,	,	y
&;		null
Thompson	thompson	np1
,	,	y
T.	t	np1
(	(	y
Eds.	eds	nn2
)	)	y
1970	1970	mc
Stimulus	stimulus	npx
properties	property	nn2
of	of	io
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
K.L.	kl	np1
,	,	y
&;		null
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E	ge	np1
.	.	y
1991	1991	mc
Subjective	subjective	jj
and	and	cc
discriminative	discriminative	jj
effects	effect	nn2
of	of	io
drugs	drug	nn2
.	.	y
Behavioural	behavioural	jj
Pharmacology	pharmacology	nn1_np1
,	,	y
2	2	mc
,	,	y
293-313	293-313	mcmc
.	.	y
<p>	<p>	y
--		zz
Preston	preston	np1
,	,	y
K.L.	kl	np1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E.	g.e	np1
,	,	y
Bickel	bickel	np1
,	,	y
W.	w	np1
,	,	y
&;		null
Liebson		np1
,	,	y
I.A.	ia	np1
1987	1987	mc
Three-choice	three-choice	jj@_nn1
drug	drug	nn1
discrimination	discrimination	nn1
in	in	ii
opioid-dependent	opioid-dependent	jj
humans	human	nn2
:	:	y
Hydromorphone		np1_vv0_nn1
,	,	y
naloxone	naloxone	nn1_vv0
and	and	cc
saline	saline	jj
.	.	y
Journal	journal	nn1
of	of	io
Pharmacology	pharmacology	np1_nn1
and	and	cc
Experimental	experimental	jj
Therapeutics	therapeutics	nn1
,	,	y
243	243	mc
,	,	y
1002-1009		mcmc
.	.	y
<p>	<p>	y
--		zz
Robinson	robinson	np1
,	,	y
T.E.	t.e	np1
,	,	y
&;		null
Berridge	berridge	np1
,	,	y
K.C.	kc	np1
1993	1993	mc
The	the	at
neural	neural	jj_nn1
basis	basis	nn1
of	of	io
drug	drug	nn1
craving	crave	vvg_nn1@
:	:	y
An	a	at1
incentive-sensitization	incentive-sensitization	jj_nn1
theory	theory	nn1
of	of	io
addiction	addiction	nn1
.	.	y
Brain	brain	nn1
Research	research	nn1
Reviews	review	nn2_vvz
,	,	y
18	18	mc
,	,	y
247-291		mcmc
.	.	y
Schuster	schuster	nn1_np1@
,	,	y
C.R.	cr	np1
,	,	y
&;		null
Balster	balster	np1_nn1
,	,	y
R.L.	rl	np1
1977	1977	mc
The	the	at
discriminative	discriminative	jj
stimulus	stimulus	nn1
properties	property	nn2
of	of	io
drugs	drug	nn2
.	.	y
In	in	ii
T.	t	np1
Thompson	thompson	np1
&;		null
P.B.	p.b	fo
Dews	dew	nn2
,	,	y
(	(	y
Eds	ed	nn2
.	.	y
)	)	y
,	,	y
Advances	advance	nn2_vvz
in	in	ii
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
,	,	y
Vol.	volume	nn1
1	1	mc1
(	(	y
pp.	pp	nnu2
85-138		mcmc
)	)	y
,	,	y
New	new	np1
York	york	np1
:	:	y
Academic	academic	jj
Press	press	nn1
.	.	y
<p>	<p>	y
--		zz
Schuster	schuster	nn1_np1
,	,	y
C.R.	cr	np1
,	,	y
Dockens	dockens	np1_nn2
,	,	y
W.S.	ws	np2
,	,	y
&;		null
Woods	woods	np1
,	,	y
J.H.	jh	np1
1966	1966	mc
Behavioral	behavioral	jj
variables	variable	nn2
affecting	affect	vvg
the	the	at
development	development	nn1
of	of	io
amphetamine	amphetamine	nn1
tolerance	tolerance	nn1
.	.	y
Psychopharmacologia	psychopharmacologia	nn1_np1@
,	,	y
9	9	mc
,	,	y
179-182	179-182	mcmc
.	.	y
<p>	<p>	y
--		zz
Shaham	shaham	np1_nn1@
,	,	y
Y.	y	np1
,	,	y
Shalev	shalev	np1
,	,	y
U.	u	np1
,	,	y
Lu	lu	np1_nn1
,	,	y
L.	l	np1
,	,	y
De	de	np1
Wit	wit	nn1
,	,	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
of	of	io
drug	drug	nn1
relapse	relapse	nn1_vv0
:	:	y
History	history	nn1
,	,	y
methodology	methodology	nn1
and	and	cc
major	major	jj
findings	finding	nn2
.	.	y
Psychopharmacology	psychopharmacology	nn1_np1@
,	,	y
168	168	mc
,	,	y
3-20	3-20	mcmc
.	.	y
<p>	<p>	y
--		zz
Sidman	sidman	nn1_np1
,	,	y
M.	m	nn1
1960	1960	mc
Tactics	tactic	nn2
of	of	io
scientific	scientific	jj
research	research	nn1
.	.	y
New	new	np1
York	york	np1
:	:	y
Basic	basic	jj
Books	book	nn2
.	.	y
Silverman	silverman	nn1_np1@
,	,	y
K.	k	np1
,	,	y
Svikis		np1_nn1
,	,	y
D.	d	np1
,	,	y
Wong	wong	np1_vv0_nn1
,	,	y
C.J.	cj	np1
,	,	y
Hampton	hampton	np1
,	,	y
J.	xx_j	np1
,	,	y
Stitzer	stitzer	np1
,	,	y
M.L.	m.l	nnu
,	,	y
&;		null
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E	ge	np1
.	.	y
2002	2002	mc
A	a	zz1_at1@
reinforcement-based	reinforcement-based	jj
therapeutic	therapeutic	jj
workplace	workplace	nn1
for	for	if
the	the	at
treatment	treatment	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
:	:	y
Three-year	three-year	jj
abstinence	abstinence	nn1
outcomes	outcome	nn2
.	.	y
Experimental	experimental	jj
and	and	cc
Clinical	clinical	jj
Psychopharmacology	psychopharmacology	nn1_np1
,	,	y
10	10	mc
,	,	y
228-240		mcmc
.	.	y
<p>	<p>	y
--		zz
Skinner	skinner	np1_nn1@
,	,	y
B.F.	bf	np1
1938	1938	mc
The	the	at
behavior	behavior	nn1
of	of	io
organisms	organism	nn2
.	.	y
New	new	np1
York	york	np1
:	:	y
Appleton-Century-Crofts	appleton-century-crofts	np1
.	.	y
<p>	<p>	y
--		zz
Stitzer	stitzer	np1_nn1@
,	,	y
M.L.	m.l	nnu
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E.	g.e	np1
,	,	y
&;		null
Liebson		np1
,	,	y
I.	i	np1
1979	1979	mc
Reducing	reducing	jj@_vvg
benzodiazepine	benzodiazepine	nn1
self-administration	self-administration	nn1
with	with	iw
contingent	contingent	jj
reinforcement	reinforcement	nn1
.	.	y
Addictive	addictive	jj
Behaviors.		np1
4	4	mc
,	,	y
245-252		mcmc
.	.	y
<p>	<p>	y
--		zz
Stitzer	stitzer	np1_nn1@
,	,	y
M.L.	m.l	nnu
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E.	g.e	np1
,	,	y
&;		null
Liebson		np1
,	,	y
I.	i	np1
1984	1984	mc
Contingent	contingent	jj
methadone	methadone	nn1
take-home	take-home	jj
privileges	privilege	nn2
:	:	y
Effects	effect	nn2
on	on	ii
compliance	compliance	nn1
with	with	iw
fee	fee	nn1
payment	payment	nn1
schedules	schedule	nn2
.	.	y
Drug	drug	nn1
&;		null
Alcohol	alcohol	nn1
Dependence	dependence	nn1
,	,	y
13	13	mc
,	,	y
395-399	395-399	mcmc
,	,	y
<p>	<p>	y
--		zz
Stitzer	stitzer	np1_nn1@
,	,	y
M.L.	m.l	nnu
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E.	g.e	np1
,	,	y
&;		null
Liebson		np1
,	,	y
I.	i	np1
1985	1985	mc
Behavior	behavior	np1_nn1
therapy	therapy	nn1
in	in	ii
drug	drug	nn1
abuse	abuse	nn1
treatment	treatment	nn1
:	:	y
Review	review	nn1_np1@_vv0@
and	and	cc
evaluation	evaluation	nn1
.	.	y
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Stitzer	stitzer	np1_nn1@
,	,	y
M.L.	m.l	nnu
,	,	y
&;		null
Vandrey	vandrey	np1
,	,	y
R.	xx_r	np1
2008	2008	mc
Contingency	contingency	nn1
management	management	nn1
:	:	y
Utility	utility	nn1
in	in	ii
the	the	at
treatment	treatment	nn1
of	of	io
drug	drug	nn1
abuse	abuse	nn1
disorders	disorder	nn2
.	.	y
Clinical	clinical	jj
Pharmacology	pharmacology	nn1
and	and	cc
Experimental	experimental	jj
Therapeutics	therapeutics	nn1
,	,	y
83	83	mc
,	,	y
644-647		mcmc
.	.	y
<p>	<p>	y
--		zz
Stoller	stoller	nn1_np1
,	,	y
K.	k	np1
,	,	y
Bigelow	bigelow	np1_vv0_nn1
,	,	y
G.E.	g.e	np1
,	,	y
Walsh	walsh	np1
,	,	y
S.L.	sl	np1
,	,	y
&;		null
Strain	strain	vv0_nn1_np1@
,	,	y
E.C	ec	np1
.	.	y
2001	2001	mc
Effects	effect	nn2
of	of	io
buprenorphine/naloxone	buprenorphine/naloxone	nn1
in	in	ii
opioid-dependent	opioid-dependent	jj
humans	human	nn2
.	.	y
Psychopharmacology	psychopharmacology	nn1_np1@
,	,	y
154	154	mc
,	,	y
230-242		mcmc
.	.	y
<p>	<p>	y
--		zz
Thompson	thompson	np1
,	,	y
T.	t	np1
,	,	y
&;		null
Schuster	schuster	np1_nn1
,	,	y
C.R.	cr	np1
1968	1968	mc
Behavioral	behavioral	jj_np1
Pharmacology	pharmacology	nn1_np1
.	.	y
Englewood	englewood	nn1_np1@
Cliffs	cliff	nn2
,	,	y
N.J.	nj	np1
:	:	y
Prentice-Hall	prentice-hall	np1
.	.	y
<p>	<p>	y
--		zz
Thompson	thompson	np1
,	,	y
T.	t	np1
,	,	y
&;		null
Schuster	schuster	np1_nn1
,	,	y
C.R.	cr	np1
1964	1964	mc
Morphine	morphine	nn1
self-administration	self-administration	nn1
,	,	y
food-reinforced	food-reinforced	nn1_jj
,	,	y
and	and	cc
avoidance	avoidance	nn1
behaviors	behavior	nn2
in	in	ii
Rhesus	rhesus	nn1
monkeys	monkey	nn2
.	.	y
Psychopharmacologia	psychopharmacologia	nn1_np1@
,	,	y
5	5	mc
,	,	y
87-94	87-94	mcmc
.	.	y
<p>	<p>	y
--		zz
Uhl	uhl	np1
,	,	y
G.R.	gr	np1
2004	2004	mc
Molecular	molecular	jj
genetics	genetics	nn1
of	of	io
substance	substance	nn1
abuse	abuse	nn1
vulnerability	vulnerability	nn1
:	:	y
Remarkable	remarkable	jj
recent	recent	jj
convergence	convergence	nn1
of	of	io
genome	genome	nn1
scan	scan	nn1_vv0
results	result	nn2
.	.	y
Annals	annal	nn2
of	of	io
New	new	np1
York	york	np1
Academy	academy	nn1
of	of	io
Sciences	science	nn2
,	,	y
1025	1025	mc
,	,	y
1-13	1-13	mcmc
.	.	y
<p>	<p>	y
--		zz
U.S.	us	np1
Department	department	nn1
of	of	io
Health	health	nn1
,	,	y
Education	education	nn1
and	and	cc
Welfare	welfare	nn1
(	(	y
USDHEW		np1
)	)	y
.	.	y
1988	1988	mc
The	the	at
health	health	nn1
consequences	consequence	nn2
of	of	io
smoking	smoking	nn1_vvg_jj
:	:	y
Nicotine	nicotine	nn1
addiction	addiction	nn1
.	.	y
A	a	at1
report	report	nn1
of	of	io
the	the	at
Surgeon	surgeon	nn1
General	general	nn1
.	.	y
U.S.	us	np1
Department	department	nn1
of	of	io
Health	health	nn1
and	and	cc
Human	human	jj_nn1
Services	service	nn2
,	,	y
Public	public	jj_nn1
Health	health	nn1
Service	service	nn1
,	,	y
Centers	center	nn2
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
,	,	y
Office	office	nn1
on	on	ii
Smoking	smoking	nn1_vvg_jj
and	and	cc
Health	health	nn1
.	.	y
DHHS	dhhs	np1
Publication	publication	nn1
No	no	xx
.	.	y
(	(	y
CDC	cdc	np1
)	)	y
88-8406		mcmc
.	.	y
<p>	<p>	y
--		zz
Vocci	vocci	nn1_np1_nn2@
,	,	y
F.	f	np1
&;		null
Ling	ling	nn1
,	,	y
W.	w	np1
2005	2005	mc
Medications	medication	nn2
development	development	nn1
:	:	y
successes	success	nn2
and	and	cc
challenges	challenge	nn2
.	.	y
Pharmacology	pharmacology	nn1_np1@
and	and	cc
Therapeutics	therapeutics	nn1
,	,	y
108	108	mc
,	,	y
94-108	94-108	mcmc
.	.	y
<p>	<p>	y
--		zz
Walsh	walsh	np1
,	,	y
S.L.	sl	np1
,	,	y
&;		null
Eissenberg		np1
,	,	y
T.	t	np1
2003	2003	mc
The	the	at
clinical	clinical	jj
pharmacology	pharmacology	nn1
of	of	io
buprenorphine	buprenorphine	nn1
:	:	y
Extrapolating	extrapolate	vvg_np1
from	from	ii
the	the	at
laboratory	laboratory	nn1
to	to	ii
the	the	at
clinic	clinic	nn1
.	.	y
Drug	drug	nn1
&;		null
Alcohol	alcohol	nn1
Dependence	dependence	nn1
,	,	y
70(Suppl)		fo
,	,	y
S13-$27		fo
.	.	y
<p>	<p>	y
--		zz
Weeks	weeks	np1
,	,	y
J.R	j.r	nna
.	.	y
1962	1962	mc
Experimental	experimental	jj
morphine	morphine	nn1
addiction	addiction	nn1
:	:	y
Method	method	nn1
for	for	if
automatic	automatic	jj
intravenous	intravenous	jj
injection	injection	nn1
in	in	ii
unrestrained	unrestrained	jj
rats	rat	nn2
.	.	y
Science	science	nn1
,	,	y
138	138	mc
,	,	y
143-144	143-144	mcmc
.	.	y
<p>	<p>	y
--		zz
Wikler	wikler	nn1_np1
,	,	y
A.	a	zz
1973	1973	mc
Dynamics	dynamics	nn
of	of	io
drug	drug	nn1
dependence	dependence	nn1
.	.	y
Implications	implication	nn2
of	of	io
a	a	at1
conditioning	conditioning	nn1
theory	theory	nn1
for	for	if
research	research	nn1
and	and	cc
treatment	treatment	nn1
.	.	y
Archives	archive	nn2
of	of	io
General	general	jj_nn1
Psychiatry	psychiatry	nn1_np1
,	,	y
28	28	mc
,	,	y
611-6l6		nn1_jj
.	.	y
<p>	<p>	y
By	by	ii
Robert	robert	np1
L.	l	np1
Balster	balster	np1_nn1
;	;	y
Sharon	sharon	np1
L.	l	np1
Walsh	walsh	np1
and	and	cc
George	george	np1
E.	e	np1
Bigelow	bigelow	np1_nn1
<p>	<p>	y
Robert	robert	np1
L.	l	np1
Balster	balster	np1
,	,	y
Ph.D.	ph.d	nna
,	,	y
is	be	vbz
Director	director	nn1
of	of	io
the	the	at
Institute	institute	nn1
for	for	if
Drug	drug	nn1
and	and	cc
Alcohol	alcohol	nn1
Studies	study	nn2
,	,	y
Butler	butler	np1
Professor	professor	nn1
of	of	io
Pharmacology	pharmacology	np1_nn1
and	and	cc
Toxicology	toxicology	np1_nn1
,	,	y
and	and	cc
Research	research	nn1_vv0@
Professor	professor	nn1
of	of	io
Psychology	psychology	nn1
and	and	cc
Psychiatry	psychiatry	nn1_np1
at	at	ii
Virginia	virginia	np1
Commonwealth	commonwealth	nn1
University	university	nn1
.	.	y
He	he	pphs1
has	have	vhz
published	publish	vvn
over	over	rg
250	250	mc
scientific	scientific	jj
articles	article	nn2
in	in	ii
animal	animal	nn1
behavioral	behavioral	nn1_jj
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
@		ii
Alcohol	alcohol	nn1
Dependence	dependence	nn1
.	.	y
<p>	<p>	y
Sharon	sharon	np1
L.	l	np1
Walsh	walsh	np1
,	,	y
Ph.D.	ph.d	nna
,	,	y
is	be	vbz
Director	director	nn1
of	of	io
the	the	at
Center	center	nn1
on	on	ii
Drug	drug	nn1
and	and	cc
Alcohol	alcohol	nn1
Research	research	nn1
,	,	y
Professor	professor	nn1
of	of	io
Behavioral	behavioral	jj_nn1_np1
Sciences	science	nn2
and	and	cc
Adjunct	adjunct	nn1
Professor	professor	nn1
of	of	io
Psychiatry	psychiatry	nn1_np1
at	at	ii
the	the	at
University	university	nn1
of	of	io
Kentucky	kentucky	np1
.	.	y
She	she	pphs1
has	have	vhz
published	publish	vvn
over	over	rg
70	70	mc
scientific	scientific	jj
papers	paper	nn2
on	on	ii
the	the	at
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
of	of	io
substance	substance	nn1
abuse	abuse	nn1
treatment	treatment	nn1
in	in	ii
humans	human	nn2
.	.	y
<p>	<p>	y
George	george	np1
E.	e	np1
Bigelow	bigelow	np1
,	,	y
Ph.D.	ph.d	nna
,	,	y
is	be	vbz
Director	director	nn1
of	of	io
the	the	at
Behavioral	behavioral	jj_np1_nn1
Pharmacology	pharmacology	nn1_np1
Research	research	nn1
Unit	unit	nn1
and	and	cc
Professor	professor	nn1
in	in	ii
the	the	at
Department	department	nn1
of	of	io
Psychiatry	psychiatry	np1_nn1
and	and	cc
Behavioral	behavioral	jj_nn1
Sciences	science	nn2
at	at	ii
Johns	john	np1
Hopkins	hopkins	np1
University	university	nn1
School	school	nn1
of	of	io
Medicine	medicine	nn1
.	.	y
He	he	pphs1
has	have	vhz
published	publish	vvn
over	over	rg
200	200	mc
scientific	scientific	jj
articles	article	nn2
on	on	ii
the	the	at
human	human	jj_nn1
behavioral	behavioral	jj_nn1
pharmacology	pharmacology	nn1
of	of	io
substance	substance	nn1
abuse	abuse	nn1
and	and	cc
on	on	ii
substance	substance	nn1
abuse	abuse	nn1
treatment	treatment	nn1
.	.	y
<p>	<p>	y
